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1.      Retrospective of lung surfactant studies 
The lung is the most important component of the respiratory system as it is 
composed of over 300 million alveoli. Alveoli are sac-like extensions at the distal end of 
the airway where gas exchange occurs. The walls of alveoli are covered by alveolar 
epithelium, which is composed of squamous alveolar epithelial type I cells (type I) and 
cuboidal alveolar epithelial type II cells (type II). Type I cells are large flat cells that 
comprise about 8% of peripheral lung cells. They cover as much as 95% of the alveolar 
surface and, along with the underlying basement membrane and capillary endothelial 
cells, form a thin air-blood barrier. In contrast, type II cells comprise about 15% of lung 
cells. They are scattered along the alveolar epithelium and form tight junctions with type 
I cells. Type II cells are the progenitors of type I cells. In normal lungs, type II cells 
proliferate with some of the daughter cells remaining type II cells and some trans-
differentiate into type I cells. The flat type I cells occupy most of the alveolar surface 
making them the most vulnerable to the damage during acute lung injuries. In response to 
injury, type II cells spread, proliferate and subsequently differentiate into hyper-plastic 
type II cells, some of which trans-differentiate into type I cells for the restoration of the 
damaged alveolar epithelium [1]. 
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Along the alveolar surface, there is a layer of thin liquid termed hypophase. 
Attraction among these water molecules generates a force, surface tension, which can 
potentially cause the alveoli to collapse and make the re-expansion of alveoli more 
difficult during inhalation. To overcome this undesirable consequence, the lung produces 
a lipoprotein-like material, called surfactant, which forms a monolayer between air and 
liquid at the air-liquid interface and dramatically reduces the surface tension of alveoli. 
This reduction subsequently increases lung compliance and prevents alveoli from 
collapsing [2, 3]. Surfactant deficiency at the alveolar surface is associated with infant 
and acute respiratory distress syndromes (IRDS & ARDS) [4]. In addition to the primary 
function of reducing surface tension, surfactant also plays a role in maintaining fluid 
homeostasis in the alveoli. Surfactant facilitates the clearance of excess fluid in alveoli by 
directing the net fluid flow across the air-blood barrier, thus preventing the formation of 
alveolar edema [5, 6]. Lung surfactant also has a role in host defense as first postulated 
first by Charles Macklin [7] and later by Ulrich Pison [8]. Along with being a physical 
permeation barrier against certain hazardous substances, surfactant also binds to various 
pathogens by surfactant protein A and D. 
The studies of possible roles for surfactant stem back to as far as 1929, when a 
Swiss physician, Kurt Von Neergaard, reported pressure-volume studies with excised 
lungs [9]. His finding strongly suggested the importance of surface tension in alveolar 
mechanics, but his findings were ignored until Edward Radford carried out similar 
experiments 25 years later that confirmed Von Neergaard’s work [10]. In 1955, R.E. 
Pattle’s work on lung edema first suggested that some material lining along the alveolar 
surface diminished surface tension to 0 mN/m [3]. It was John A. Clements who first 
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provided direct evidence for the presence of a surface active material at the alveolar 
surface [2]. Clements et al. also suggested that dipalmitoylphosphatidylcholine (DPPC) is 
the major surface active component in surfactant. Their work enlightened the active 
investigations of surfactant and leading to Mary Avery and James Mead’s 1959 discovery 
that there is an association between infant RDS and the absence or delayed appearance of 
lung surfactant [11]. A variety of studies from G.C. Liggins [12] showed that 
corticosteroid treatment accelerated fetal lung maturation and the onset of surfactant 
production, which led to the first clinical trial in which the administration of 
corticosteroid to pregnant women prevented the occurrence of IRDS. In 1980, T. 
Fujiwara carried out a promising clinical trial by treating babies suffering IRDS with 
exogenous surfactant isolated from bovine lungs [13]. This report gave momentum for 
studies that aimed to design well-defined surfactant preparations for safe replacement 
therapy.  
Soon after the discovery of surfactant, questions remained as to what cells produced 
surfactant and how long it stayed in the alveoli. These questions were difficult to answer 
because the lung contains about 40 different types of cells and surfactant is not a single 
molecule but a mix of lipids and proteins. As early as 1954, type II cells were postulated 
to be the makers of surfactant [7]. It was also proposed early on that lamellar bodies of 
type II cells serve as the storage site of surfactant prior to its secretion into alveolar 
surface [14, 15]. In 1972, G. Chevialer provided strong evidence that type II cells are the 
major, if not the only, cells to produce surfactant [16]. Many studies have been carried 
out to reveal the pathways and regulation of surfactant synthesis, secretion and recycling 
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thanks to the advances in techniques for type II cell isolation and lamellar body 
fractionation [17-19]. 
2.     Surfactant biochemistry 
Lung surfactant is somewhat like the cell membrane in that it is rich in lipids and 
proteins. From the numerous biochemical studies of bronchoalveolar lavage (BAL) 
material, lung surfactant is known to be composed of about 10% of protein and 80-90% 
of lipid by weight. More than 80% of lipids are phospholipids, whereas cholesterol 
comprises the largest amount of neutral lipids [20, 21]. Phosphatidylcholine (PC) is the 
major phospholipid component (60-70%) in surfactant. Other phospholipid components 
include phosphatidylglycerol (PG) (5-10%), phosphatidylethanolamine (PE) (5-10%), 
phosphatidylinositol (PI) and phosphatidylserine (PS) (PI + PS = 3-6%). Surfactant 
contains an unusually high level of saturated-fatty-acid-chained lipids, predominantly 
DPPC, which contributes substantially to the unique function of surfactant in the 
reduction of surface tension in the extracellular surfactant film at the air-liquid interface 
[22]. Phospholipids contain a glycerol backbone, a polar head and a non-polar tail. This 
structure allows phospholipids to fit in between water molecules to disrupt the formation 
of hydrogen bonds, thus reducing the surface tension resulted from water molecule 
interaction. 
Besides lipids, surfactant proteins are also required for the formation and 
maintenance of surfactant film at the alveolar surface [13, 23]. There are four surfactant 
proteins designated as SP-A, SP-B, SP-C and SP-D. Both SP-A and SP-D are hydrophilic 
proteins that contain N-terminal collagen-like domains and a C-terminal lectin-like 
domain. The C-terminal domain harbors calcium and carbohydrate binding sites. SP-A is 
 4
able to bind lipids and carbohydrate as well as specific cell receptors and is involved in a 
variety of lung surfactant functions. SP-A is essential for promoting the transformation of 
lamellar bodies into tubular myelin [24, 25]. SP-A has the ability to self-aggregate at a 
physiological extracellular calcium concentration, and this aggregation is believed to be 
important for the SP-A-induced formation of tubular myelin [26, 27]. In RDS patients, a 
lack of tubular myelin was found together with a loss of SP-A, which supports the role of 
SP-A in tubular myelin formation [28]. Another function of SP-A is to regulate surfactant 
homeostasis. SP-A was reported to mediate the endocytosis of recycling surfactant [29], 
as well as inhibit surfactant exocytosis [30]. Since SP-A contains the carbohydrate 
binding site, it also has the ability to recognize and bind lipopolysaccharides (LPS) from 
Gram-negative bacteria [31], which enhances alveolar macrophage migration and 
phagocytosis [32]. The main function of SP-D is to modulate innate immunity and 
pulmonary host defense. Like SP-A, SP-D binds to the surface of pathogens like bacteria 
[33, 34] and viruses [35] for the facilitation of their elimination by macrophages [36]. 
Both SP-A and SP-D knockout mice showed abnormal responses against bacterial and 
viral challenges [37]. One surprising finding about SP-D is that it binds PI in a calcium-
dependent manner, which may indicate a role of SP-D in intracellular lipid sorting and/or 
signal transduction [38, 39]. 
SP-B and SP-C are highly hydrophobic and are intimately involved in the function 
of surfactant. They play important roles in the stability and spreading of surfactant along 
alveoli. SP-B and SP-C are synthesized and packed with phospholipids in lamellar bodies. 
SP-B is a small protein with 79 amino acid residues that contains 3 characteristic 
intramolecular disulfide bonds out of its 7 cysteine residues. The one free cysteine 
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residue forms intermolecular disulfide bond required for its dimerization [40, 41]. The 
most important function of SP-B is to promote the formation of stable surfactant film by 
mediating the phospholipid insertion into the air-liquid interface [42, 43]. It is also 
required for tubular myelin formation [24] and proteolytic processing of SP-C. SP-B 
knockout mice died of RDS shortly after birth. SP-C has only 35 amino acid residues. In 
addition to its high content of valine residues, the palmitoylation of the cysteine residues 
makes SP-C extremely hydrophobic. SP-C is also able to promote the phospholipid 
insertion into the air-liquid interface in a calcium-dependent manner [43] and regulate 
phospholipid ordering [44, 45].  
3.    Biogenesis of surfactant and lamellar bodies 
Autoradiographic [16] and immunocytochemical [46] studies have demonstrated 
that most components of surfactant are synthesized in the endoplasmic reticulum of type 
II cells. The precursors for synthesis of surfactant lipids in type II cells include glycerol, 
fatty acids, acyl chains and other head groups. The glycerol backbone used for surfactant 
lipid synthesis is mainly from circulating glucose [47], while the fatty acids are supplied 
from several sources: circulation [48], the hydrolysis of recycled phospholipids up-taken 
from alveoli [49] and synthesis de novo [50]. Mammalian tissues do not synthesize free 
choline and the choline required for PC synthesis is likely from the diet [51]. Myo-
inositol required for PI formation can be synthesized in the body, while additional 
supplementation of inositol from the diet has also been reported [52, 53].The first step of 
surfactant phospholipid synthesis is the formation of phosphatidic acid (PA) from 
glycerol-3-phosphate derived from glycerol or glucose with two sequential acylation 
reactions. To synthesize PC, PA is hydrolyzed to diacylglycerol by phosphatidate 
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phosphatase. Intracellular triacylglycerol might be an additional source by the action of 
triacylglycerol lipase [54]. With the sequential actions of choline kinase and choline-
phosphate cytidylyltransferase, the cytidine 5’-diphosphate (CDP) group is added to free 
choline. The competent choline group is then transferred to diacylglycerol to form PC by 
the action of cholinephosphotransferase. For the formation of PG and PI, phosphatidate 
cytidylyltransferase catalyzes PA to convert into CDP-diacylglycerol, from which PI can 
be synthesized by the reaction with myo-inositol catalyzed by CDP-diacylglycerol-
inositol phosphatidyltransferase. CDP-diacylglycerol can also be converted by 
glycerolphosphate phosphatidyltransferase into phosphatidylglycerolphosphate, which is 
subsequently dephosphorylated into PG by phosphatidylglycerophosphatase. The 
synthesis of PE is similar to that of PC, in which an ethanolamine group is added to 
diacylglycerol by ethanolaminephosphotransferase. PS is likely produced by a head 
group switch from PC or PE. Most of the cholesterol is from circulating low-density 
lipoprotein (LDL) or high-density lipoprotein (HDL) and the synthesis in the lung is 
negligible [55].  
Among the 4 surfactant proteins, SP-C is only synthesized in type II cells [56, 57]. 
SP-A, SP-B and SP-D are synthesized in both bronchiolar Clara cells and type II cells 
[58-60]. The primary translation product of SP-A preprotein contains a 20 amino acid 
hydrophobic signal peptide, by which the preprotein attaches and traverses the 
endoplasmic reticulum. The signal peptide is then cleaved to allow the preprotein into the 
endoplasmic reticulum lumen. Posttranslational modifications of SP-A include 
hydroxylation [61], glycosylation [62], sialyation [63], sulfation and sulfhydryl-
dependent oligomerization [64]. Mature SP-A is mainly released into alveoli through a 
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constitutive pathway other than via lamellar bodies [65, 66]. The translated SP-B 
preprotein is about 42 kDa with a 23 amino acid N-terminal signal peptide. After 
cleavage of the flanking sequences at both C- and N-termini, the mature SP-B is 
eventually transported into lamellar bodies where the homodimerization occurs [41]. SP-
C cDNA is about 3.5 kb and is translated into a 179 amino acid preprotein. The N-
terminus of the preprotein is required for its sorting to the secretion pathway [67], while 
the C-terminus has been shown to play a role in intracellular transportation [68]. The 
palmitoylation of cysteine residues takes place in the Golgi apparatus and it is important 
for lamellar bodies to maintain a dense packing [69]. Like SP-A, SP-D undergoes 
posttranslational modifications, such as hydroxylation and glycosylation and is capable of 
forming homo-oligomers [70, 71]. SP-D is localized in the ER but not in lamellar bodies 
[60, 72], which indicates that it is secreted via a constitutive pathway.  
Lamellar bodies are lysosome-related organelles and mature lamellar bodies are one 
of the largest secretory granules in the cell, ranging from 1 to 2 μm in size. Similar to 
lysosomes, lamellar bodies contain soluble lysosomal enzymes and proteins, such as acid 
phosphatase and lysosome associated membrane proteins (LAMP) [73-75] and an acidic 
interior (pH about 6.1 or below) [76, 77]. In rat lungs, lysozymes were found in lamellar 
bodies on type II cells [78]. However, lamellar bodies are different from lysosomes in 
that they are specialized for storage and secretion of surfactant rather than for degradation. 
Phospholipids are the principle components and are tightly packed within lamellar bodies, 
being well organized as concentric arrangements of bi-layer membranes. There is a high 
level of calcium present inside lamellar bodies and part of its significance might be for 
sequestering acidic phospholipids, which could produce charge repulsion and disrupt 
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membrane packing. Lamellar body formation requires SP-B and ABCA3. ABCA3 is a 
member of the ATP Binding Cassette family of ATP-dependent membrane associated 
transport proteins. ABCA3 is expressed exclusively in alveolar type II cells and localized 
on lamellar bodies [79-81]. Like ABCA1 and ABCA4, ABCA3 may function as a lipid 
transporter in type II cells and is essential for the formation of lamellar bodies. ABCA3-
knockout mice died of RDS within one hour after birth even with the gross lung 
developed normally. However, no mature lamellar bodies were found and the surfactant 
was absent in the alveolar space [82, 83]. 
Lamellar bodies originate from the endoplasmic reticulum and then travel via the 
Golgi complex as an intermediate form. Multi-vesicular-bodies (MVBs) are early 
manifestations. The mature lamellar bodies are transported to apical area of type II cells 
[84]. By combining electron microscopy and autoradiography techniques, newly 
synthesized surfactant protein was sequentially detected in the ER, Golgi, MVBs and 
lamellar bodies in type II cells. After synthesis, surfactant lipids are transferred via the 
Golgi apparatus to small immature lamellar bodies while proteins are transferred into 
MVBs [16, 85]. There are two types of MVBs. Large MVBs (l-MVB) with an electron 
lucent matrix are localized mainly at the apical area and contain SP-A. The smaller 
MVBs with an electron dense matrix (d-MVB) are mainly localized at the basolateral 
area and contain lysosomal activity [86]. In addition to MVBs, the composite body, an 
unusual organelle, contains lipid bilayers and might be derived from the fusion of MVBs 
and lipid-containing immature lamellar bodies. The fully mature lamellar bodies 
eventually fuse with the apical plasma membrane and release surfactant into the alveolar 
space. 
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The surfactant system is very dynamic. For example, phosphatidylcholine, the 
predominant component of surfactant, has a half life of only a few hours and about 85% 
of it is recycled [87]. All components of surfactant, including lipids and all 4 surfactant 
proteins, have been demonstrated to undergo re-uptake and recycling [88-91]. SP-A, B, C 
and anionic phospholipids have been reported to stimulate the uptake of isolated type II 
cells [92, 93] while SP-D is ineffective [88]. At least in the case of SP-A, the uptake is 
through receptor-mediated endocytosis [29, 94]. The majority of the re-uptake 
components, especially PC, are incorporated into lamellar bodies via MVBs for reuse, 
while the rest is degraded in lysosomes for surfactant synthesis or completely out of 
surfactant system. 
4.   Surfactant secretion 
Surfactant secretion has been studied in various models from intact animals to 
isolated type II cells [30, 95-97]. The latter is the most utilized. The lipid components of 
surfactant are secreted through lamellar bodies in a highly regulated pathway. The 
hydrophobic SP-B and SP-C are secreted with surfactant lipids together, while SP-A and 
SP-D are through constitutive routes independent of lamellar bodies. Secretion of 
surfactant is regulated by a variety of chemical or physical stimuli. Distension of the lung 
is the most physiologically relevant stimulus. This can directly act on type II cells [98-
100], or indirectly through type I cells [101-104]. In the latter case, the inflation-induced 
calcium signal in type I cells can pass on to type II cells through gap junctions [105]. 
Other pharmacological agents include β-adrenergic and adenosine A2B receptor agonists, 
purinergic P2Y2 receptor agonists (ATP), forskolin, cholera toxin, tetradecanoyl-phorbol-
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acetate (TPA) and calcium ionophores (A23187). There are at least 3 signal transduction 
pathways involved in the regulation of surfactant secretion. 
The first pathway involves the activation of G protein-coupled adenylate cyclase 
after β-adrenergic or adenosine A2B receptors are stimulated. Adenylate cyclase 
generates cAMP and subsequently activates cAMP-dependent protein kinase A (PKA). 
Cholera toxin directly activates G protein, and forskolin directly activates adenylate 
cyclase.  
The second mechanism involves the activation of the protein kinase C (PKC) 
pathway. TPA directly activates PKC. ATP binds the P2Y2 receptor and activates 
phospholipase C (PLC), which hydrolyzes phosphatidylinositol bisphosphate (PIP2) into 
diacylglycerol (DAG) and inositol trisphosphate (IP3). The DAG-activated PKC 
subsequently may activate phospholipase D (PLD), which hydrolyzes PC into choline 
and PA. Phosphatidate phosphatase converts PA into DAG, which further activates PKC. 
The third pathway involves the increase in the intracellular calcium levels. Calcium 
ionophores promote calcium influx into the cell and the IP3 from the PIP2 hydrolysis can 
stimulate the release of calcium from intracellular compartments, such as the 
endoplasmic reticulum. The increased calcium level activates a calcium-calmodulin-
dependent protein kinase (CaMK). In type II cells, the presence of CaMK II has been 
demonstrated by Western blotting. Meanwhile, the Ca2+ ionophore A23187-stimulated 
phosphatidylcholine secretion was inhibited by KN-62, a specific CaMK II inhibitor, in a 
dose-dependent manner in isolated type II cells [106].  
After one or multiple activations of the signal transduction pathways, the target 
proteins are phosphorylated, ultimately leading to surfactant secretion. The precise 
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mechanisms are still unclear, while certain factors have been reported to play some roles 
during the process. Calpains are Ca2+-dependent cysteine proteases and have been 
reported to be activated by secretagogues in type II cells [107]. Calpains partially 
proteolyze PKA in stimulated type II cells, and this limited proteolysis may convert the 
initial transient signal into sustained and augmented phosphorylation activity for 
secretion [108]. Meanwhile, the suppression of calpains significantly inhibited the TPA-
stimulated secretion in type II cells [109]. In addition, arachidonic acid has been shown to 
stimulate secretion in cultured type II cells [110, 111] and promote annexin A2-mediated 
fusion between isolated lamellar bodies and the plasma membrane [112]. Arachidonic 
acid is generated through the work of cytosolic phospholipase A2 (cPLA2) and DAG 
lipase. The blockage of cPLA2 or DAG lipase activity has been shown to inhibit the 
secretion in type II cells [113]. These results further confirm the involvement of 
arachidonic acid in surfactant secretion.  
The processes by which lamellar bodies are translocated to the area of the apical 
plasma membrane are still not known. It has been postulated that actin [114] and 
microtubules [115] play a role for the transportation of lamellar bodies and intermediate 
filaments may function as guides [115]. The sub-apical cytoskeletal network of F-actin 
has to be dissembled for lamellar bodies to be transported to the apical membrane [116]. 
In stimulated type II cells, the cytoskeleton undergoes disassembly and assembly and 
annexin A2 may play a role in this process [117]. Once lamellar bodies reach the plasma 
membrane, annexins may facilitate their fusion with the plasma membrane [118, 119].  
The secretion occurs by merging the limiting membrane of lamellar bodies with the 
plasma membrane and forming a fusion pore, through which the surfactant is released out 
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of the cells into alveolar lumen [120, 121]. Morphological and functional evidence has 
demonstrated that fusion pores in type II cells are pretty stable [122, 123]. By using 
fluorescent dye FM 1-43, fusion pores are found to expand slowly, but the expansion 
accelerates as calcium concentration increases [124]. Fusion pore structures have been 
studied on both artificial bilayers [125, 126] and biological membranes [127-130]. A 
“stalk-pore” hypothesis has been postulated to explain its formation. It starts with the 
contact between the fusing membranes mediated by tethering molecules, like a viral 
fusion peptide [131] or a hairpin structure composed of membrane proteins on opposing 
membranes [132].  The reduction of repulsion between two opposing membrane bilayers 
may result in a relaxation in the merging of the proximal bilayers. Thus, the proximal 
monolayers are connected with a highly bent stalk and the distal monolayers are pulled 
toward each other to form a dimple. This is referred to as hemifusion state and is thought 
to be a prerequisite for the formation of a fusion pore [133]. Following hemifusion, an 
expanding fusion pore opens and the content is released. Haller et al. proposed that the 
diameter of fusion pores might be the rate-limiting step for the surfactant secretion [123]. 
The observation of increased surfactant secretion in stretched type II cells might be due to 
widening by direct mechanical forces. Since the molecular composition of fusion pores is 
still unknown, understanding how fusion pores form remains a challenge.  
5.     SNARE 
One of the fundamental features of eukaryotic cells is the compartmentalization into 
membrane-bound and biochemically distinct organelles. However, various molecules 
need to be transported to their correct destinations without compromising the membrane 
integrity. To achieve this, elaborate mechanisms have been developed to transport 
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vesicles budding from one compartment and then target and fuse to the destination 
compartment. Over the last decade, Soluble N-ethylmaleimide-sensitive-factor 
Attachment protein Receptor (SNARE) proteins have attracted much attention and are 
considered the most important protein family involved in membrane trafficking, docking 
and fusion.  
The discovery of SNARE proteins followed the identification of SNARE-associated 
proteins. The Rothman group [134] first isolated an ATPase, which can be inactivated by 
N-ethylmaleimide and was termed as (NSF). Subsequently, the adaptor proteins for NSF 
were identified as α-, β-, γ- soluble NSF attachment protein (SNAP) [135]. SNARE 
proteins were then isolated from brain extract co-precipitated with α-SNAP and NSF 
[136]. Subsequently, the SNARE protein family has been demonstrated to play a central 
role not only in neurotransmitter release in synapses, but also in intracellular trafficking 
events.  
Trying to address the molecular mechanisms of membrane fusion, Rothman 
postulated the so-called SNARE hypothesis [137]. With a substantial body of evidence 
from a number of research groups, a general principle about how SNARE proteins 
function in membrane fusion states as follows. The SNAREs from the opposing 
membrane contain characteristic coiled-coil SNARE motifs, which assemble into a trans-
SNARE complex and pull the membranes to a close position. After the membrane fusion, 
the SNARE complex (cis-SNARE) is dissembled with the energy from ATP hydrolysis 
by NSF via the adaptor α-SNAP [138, 139]. The free SNAREs are available for the next 
round of membrane fusion.   
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SNARE proteins are membrane proteins which form hetero-oligomeric complexes. 
According to their subcellular localizations on vesicle or target membranes, SNARE 
proteins can be classified into vesicle-SNAREs (v-SNAREs) and target SNAREs (t-
SNAREs), respectively. v-SNAREs include the vesicle-associated-membrane-protein 
(VAMP) family, while t-SNAREs include syntaxins and SNAP-25 (synaptosome 
associated protein of 25 kDa) family. SNARE proteins contain a conserved coiled-coil 
domain of 60-70 amino acids in length, which is termed as the SNARE motif [140]. 
Based on whether a conserved glutamine (Q) or arginine (R) is present at the zero-layer 
of the SNARE motifs, a second classification system has been proposed [141]. In practice, 
Q-SNAREs are almost always t-SNAREs and R-SNAREs are v-SNAREs. Mostly, a 
given set of cognate SNARE proteins involved in a certain fusion reaction includes one 
R-SNARE and three Q-SNARE motifs [142, 143]. 
There are 15 mammalian syntaxin genes, and syntaxin 1-4 are localized to the 
plasma membrane and function in exocytotic processes  [144]. Besides the coiled-coil 
SNARE motif, syntaxins contain a transmembrane domain at the C-terminus, through 
which syntaxins attach to the membrane and a unique N-terminal sequence.  Syntaxin 1A 
has a bundle of three α-helices at the N-terminal sequence in a twisted left-handed up-
down bundle, termed as Habc domain [145]. By folding of Habc upon the SNARE motif, 
syntaxin 1A adopts a closed conformation. n-Sec1/Munc18-1 binds to this closed 
conformation of syntaxin to prevent the formation of the SNARE complex  [146-149]. 
The activation of the Rab small GTPase could induce the dissociation of n-Sec1/Munc18 
and the binding of Munc-13 to syntaxin 1A, which subsequently adopts the open 
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conformation and renders the SNARE motif available for SNARE complex formation  
[150]. 
SNAP-25 is specific in neuronal and neuro-endocrine systems and its non-neuronal 
homologue SNAP-23 is ubiquitously expressed and localized at the plasma membrane 
[151, 152]. SNAP-29 is localized in many intracellular membranes and is not thought to 
be involved in exocytotic regulation [153, 154]. SNAP-25 family members contain two 
SNARE motifs at both the N- and C-termini, which are connected by a cysteine-rich 
linker sequence. Unlike syntaxins, the SNAP-25 family does not contain a 
transmembrane domain and is associated with the membrane via the palmitoylation of the 
cysteine residues in the linker region [155-158]. SNAP-25 has four cysteine residues, 
while SNAP-23 contains five. In SNAP-25, one single cysteine mutation could reduce the 
palmityolation significantly [159]. Brefeldin A, an agent blocking the transport through 
the Golgi, abolished SNAP-25 palmitoylation [160]. Meanwhile, the plasma membrane is 
enriched in palmitoylacyl transferase activity, especially in lipid rafts [161, 162], where 
SNAP-25 and SNAP-23 associate [163, 164]. This indicates that palmitoylation occurs at 
the lipid raft of the plasma membrane. 
The VAMP family has seven members. VAMP proteins contain a single SNARE 
motif and attach to the vesicle membrane via a C-terminal transmembrane domain. 
VAMP-2 is initially identified as v-SNARE of synaptic vesicles in neurons and plays an 
important role in synaptic vesicle exocytosis [165]. Besides in synaptic vesicles, VAMP-
2 is also extensively studied in the endocrine system and other non-neuronal tissues and 
is involved in regulated intracellular transport events, such as in PC12 cells, the adrenal 
medulla, and the pancreas [163, 166-174]. VAMP-1 is highly homologous to VAMP-2 
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but has a differential distribution pattern. It is involved in calcium-dependent synaptic 
vesicle exocytosis [175-177]. VAMP-1 is also expressed in non-neuronal tissues [178], 
but its function is not clear. VAMP-3 is ubiquitously expressed and preferentially 
associated with early/recycling endosomes. VAMP-3 was reported to play an important 
role in platelet alpha granule secretion by using tetanus toxin [179], antibody [180], and 
the cytoplasmic domain  [181]. However, the results from VAMP-3 knock-out mice 
indicate that it is not essential for secretion [182]. VAMP-7 is also termed as TI-VAMP, 
due to its resistance against tetanus neurotoxin cleavage [183]. VAMP-7 is associated 
with the late endosomes and involved in endocytosis and intracellular trafficking between 
ER and Golgi [184, 185]. VAMP-8 is associated with the endocytic pathway and 
involved in the fusion between early and late endosomes [186, 187]. It has recently been 
reported to be required in regulated exocytosis in pancreatic acinar cells [188] and 
platelets [189].  
In our laboratory, we demonstrated the presence of syntaxin 2 and SNAP-23 and 
SNARE associated proteins, NSF and α-SNAP in type II cells and they were also found 
to be required in the regulated surfactant secretion [190, 191].  
6.   Annexin A2 
Intracellular Ca2+ signaling and homeostasis have an essential role in regulating 
many cellular processes in eukaryotic organisms. Annexins are a family of Ca2+-binding 
protein which differ from other Ca2+-binding proteins by the unique architecture of their 
Ca2+-binding sites. This feature enables annexins to peripherally bind to negatively 
charged membranes in a reversible manner, which links annexins to many membrane 
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related events, such as membrane organization, membrane-cytoskeleton linkage, 
membrane transportation and ion conductance across membranes.  
As a member of the annexin family, annexin A2 plays an important role in various 
aspects of vesicular trafficking [192, 193]. It has been shown to be involved in Ca2+-
dependent membrane fusion during exocytosis and endocytosis in a variety of cells, 
including chromaffin cells and alveolar type II cells [194-198]. Among the annexin 
family, annexin A2 has been shown to require the least Ca2+ concentration for membrane 
binding and lipid vesicle aggregation at sub-μM to a few μM [199]. In our laboratory, 
annexin A2 has also been demonstrated as the most effective annexin to mediate fusion 
between lamellar bodies and the plasma membrane [112]. This makes annexin A2 the 
most attractive candidate for mediating calcium-dependent exocytosis. Annexin A2 exists 
as a 36 kDa monomer (AIIm) or as a heterotetramer (AIIt) in which two monomers bind 
to a pair of p11, an S100 family protein [200]. Annexin A2 consists of two functional 
domains. The C-terminal domain contains the annexin core domain, which harbors the 
binding sites for Ca2+, phospholipids [201, 202] and F-actin [203, 204]. Unlike other 
calcium-binding proteins exemplified by calmodulin, which bind calcium via an “E-F 
hand” helix-loop-helix domain, annexin A2 binds calcium via the core domain. The core 
domain is conserved within the annexin family and is composed of 4 tandem annexin 
repeats (except for annexin A6 which has 8), each of which is about 70 amino acids in 
length. The core domain is a compact, slightly curved disc in shape. Its convex side is the 
sites for calcium and membrane binding. On the other side, the concave surface points 
away from the membrane and thus is available for the interactions with other proteins. 
Therefore, annexin A2 may provide a platform to recruit other components involved in 
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calcium-dependent membrane events. The N-terminal sequences are highly variable 
among annexin members. At the N-terminal domain of annexin A2, the first 30 amino 
acids contain the p11 binding site [201, 205, 206] and serine and tyrosine 
phosphorylation sites [207, 208]. The presence of the partner-binding and 
phosphorylation sites in the variable N-terminus suggests that this region renders 
annexins’ characteristic features distinct from each other and is likely to be of regulatory 
importance. In the case of annexin A2, the N-terminal domain plays a very important role 
in regulating the Ca2+ requirement for annexin A2 activities. The annexin A2 monomer 
aggregates chromaffin granules with a Kd (Ca2+) of about 1 mM. The proteolytic 
cleavage of the N-terminal significantly decreases the Kd (Ca2+). Furthermore, the 
binding of p11 reduces the Ca2+ requirement down to about 2 μM [209]. Moreover, the 
phosphorylation of the tyrosine or serine residue significantly affects the activity of 
annexin A2 in chromaffin granule aggregation [210] or calcium-evoked secretion in 
permeabilized chromaffin cells [197]. Annexin A2 mediates the aggregation and fusion 
of liposomes in the presence of Ca2+ [196, 211]. The modifications of cysteine or tyrosine 
residues of annexin A2 by nitric oxide or peroxynitrite abolished its capability to mediate 
liposome aggregation [212, 213]. The depletion of annexin A2 from type II cell cytosol 
reduces its membrane fusion activity [112]. Most recently, we have demonstrated that the 
silencing of the annexin A2 gene by RNAi significantly decreases the secretion of 
surfactant in isolated type II cells [214]. These results suggest that annexin A2 
participates in the process of regulated surfactant secretion. 
7.  Purposes and Significance 
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The presence of lung surfactant at the alveolar space is vital for air exchange. The 
deficiency of surfactant results in RDS. Although it has been studied for a long time, 
RDS is still a leading cause of infant death in the United States. Lung surfactant is 
synthesized and stored in lamellar bodies in type II cells prior to its secretion into the 
alveolar space. The secretion of surfactant is a highly regulated process and involves the 
translocation, docking and fusion of lamellar bodies with the apical plasma membrane. 
However, the mechanisms of surfactant secretion still remain vague.  
SNARE proteins play an essential role in intracellular transport and membrane 
fusion. It has been demonstrated in our laboratory that t-SNAREs, syntaxin 2 and SNAP-
23, are present in type II cells and required for regulated surfactant secretion. However, 
regulated surfactant secretion is a calcium-dependent process, and a role for calcium 
sensors needs to be fulfilled. Annexin A2 is a calcium-binding protein and it has also 
been reported to be involved in regulating surfactant secretion. The first part of my 
project (Chapter II) attempted to investigate whether annexin A2 and SNARE proteins 
work in the same pathway to regulate lung surfactant. By using different techniques, 
SNAP-23 was found to be the SNARE protein interacting with annexin A2 physically 
and functionally. The cysteine rich region of SNAP-23 is essential for the interaction. 
The second part of my work (Chapter III) was to characterize v-SNARE proteins in 
type II cells. VAMP-2, 3 and 8 were found to be expressed in lung and type II cells at 
both mRNA and protein levels and VAMP-2 was found to be localized on lamellar 
bodies.  
To better understand the molecular mechanisms of lamellar body biogenesis and its 
translocation, docking and fusion with the plasma membrane, a proteomic analysis of 
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isolated lamellar bodies was carried out (Chapter IV). Utilizing peptide mass 
fingerprinting by MALDI-TOF, 44 proteins have been identified and categorized 
according to their functions, including proteins involved in membrane trafficking, 
calcium binding and signal transduction. The proteomic profiling of lamellar bodies 




Interaction of Annexin A2 and SNAP-23 is Required in Annexin A2 Tetramer-Mediated 
Fusion between Lamellar Bodies and the Plasma Membrane 
 
Abstract 
Lung surfactant is secreted through the fusion of large granules, lamellar bodies with 
the plasma membrane of alveolar epithelial type II cells. Annexin A2, a Ca2+- and 
phosphlipid-binding protein, promotes the fusion of lamellar bodies with the plasma 
membrane in vitro. Our previous studies have indicated an essential role of the soluble N-
ethylmaleimide-sensitive-factor attachment protein receptors (SNARE) in surfactant 
secretion. We hypothesized that annexin A2 acts as a Ca2+ sensor and mediates 
membrane fusion via its interaction with SNAREs. Here, we investigated the physical 
and functional interactions between annexin A2 and SNARE proteins. Glutathione S-
Transferase (GST) pull-down experiments showed that SNAP-23 specifically bound with 
annexin A2 in a Ca2+-dependent manner. Immunofluorescence revealed co-localization of 
SNAP-23 and annexin A2 in intact type II cells. The deletion study identified the 
cysteine-rich region (CRR) of SNAP-23 as the binding site for annexin A2. The 
mutations of cysteine residues in CRR dramatically decreased the binding. SNAP-23 was 
co-immunoprecipitated with annexin A2, while a SNAP-23 mutant lacking CRR failed to 
do so. The results indicated a direct interaction between SNAP-23 and annexin A2 in 
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cells. Furthermore, anti-SNAP-23 antibody significantly inhibited annexin A2-mediated 
fusion between lamellar bodies and the plasma membrane. These data suggest that 
annexin A2 and SNAP-23 are involved in the same pathway in the regulation of lung 
surfactant secretion.  
 




Lung surfactant is a surface active material, which forms a monolayer at the air-
liquid interface and reduces the surface tension of alveoli, thus preventing alveoli from 
collapse. Deficiency of surfactant at the alveolar surface is associated with infant and 
acute respiratory distress syndromes. Lung surfactant is synthesized and secreted by 
alveolar type II cells. It is composed of phospholipids, mainly 
dipalmitoylphosphatidylcholine (DPPC), and surfactant proteins A, B, C, and D. Most 
components of surfactant are synthesized in endoplasmic reticulum and stored in the 
specified organelles, lamellar bodies. Secretion of surfactant involves the translocation, 
docking and fusion of lamellar bodies with the apical plasma membrane. This process is 
very complicated and the underlying mechanism is still poorly understood [95, 96, 215, 
216].  
Soluble N-ethylmaleimide-sensitive-factor Attachment protein Receptors (SNAREs) 
are a protein family, which exist ubiquitously in eukaryotic cells and play crucial roles in 
membrane targeting, docking, and fusion [132, 137, 217-219]. The vesicle SNARE (v-
SNARE), vesicle associated membrane protein (VAMP), is located on the membrane of 
secretory vesicles while the target SNAREs (t-SNARE), syntaxin and SNAP-25/SNAP-
23, are located on the plasma membrane. SNARE proteins contain the characteristic 
coiled-coil domains, termed as SNARE motifs, which are approximately 60-70 residues 
in length [140]. The interaction of the SNARE motifs from cognate SNARE proteins in 
two adjacent membranes forms a trans-SNARE complex to pull the membranes into close 
apposition, and eventually leads to membrane fusion [220]. Rothman and colleagues 
reconstituted SNARE proteins into liposomes to simulate the membrane fusion in vitro 
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and proposed that the SNARE proteins provided the minimal fusion machinery [221-223]. 
However, the speed was too slow to be physiologically. Furthermore, two recent studies 
demonstrated that inter-membrane SNARE interactions in the SNARE-reconstituted 
liposome systems with more native SNARE densities did not drive membrane fusion 
[224, 225].  An elevation of cytosolic Ca2+ concentration is required to trigger regulated 
exocytosis [226]. Synaptotagmin I was found to increase the fusion of liposomes 
reconstituted with SNAREs in a Ca2+-dependent manner, demonstrating its role in Ca2+–
triggered exocytosis [227]. On the other hand, the hippocampal neurons from 
synaptotagmin I knock-out mice still can release neurotransmitter although the kinetics of 
the release was affected [228]. With the studies of the Ca2+-triggered fusion of sea urchin 
cortical vesicles in vitro, Zimmerberg and colleagues [229-232] proposed that SNARE 
proteins might just play a modulatory role, acting at the upstream targeting and docking 
stages. Disruptions of these steps by attacking SNARE proteins with neurotoxins, 
antibodies or other chemicals would alter the overall exocytotic process, while some 
other proteins associated with SNARE proteins might actually mediate the final fusion 
step(s). Mayer and colleagues reported V-ATPase V0 sector as a membrane fusogen 
acting downstream and independent of trans-SNARE complex formation [233, 234]. 
These data suggest the possibility that additional proteins exist, which may act as Ca2+ 
sensor and/or fusogenic proteins. 
Annexin A2 is a Ca2+-dependent phospholipid-binding protein, which plays an 
important role in various aspects of vesicular trafficking [192, 193]. It has been shown to 
be involved in Ca2+-dependent membrane fusion during exocytosis and endocytosis in a 
variety of cells, including chromaffin cells and alveolar type II cells [194-198]. Annexin 
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A2 exists as a 36 kDa monomer (AIIm) or as a heterotetramer (AIIt) in which two 
monomers bind to a pair of p11, an S100 family protein [200]. Annexin A2 binds to 
negatively charged phospholipids and mediates the aggregation and fusion of liposome in 
the presence of Ca2+ [196, 211]. The modifications of cysteine or tyrosine residues of 
annexin A2 by nitric oxide or peroxynitrite abolished its capability to mediate liposome 
aggregation [212, 213]. The depletion of annexin A2 from alveolar type II cell cytosol 
reduced its membrane fusion activity [112]. Most recently, we demonstrated that the 
silencing of annexin A2 gene by RNAi significantly decreased the secretion of surfactant 
in isolated alveolar type II cells [214].   
Based on our previous studies that SNARE proteins and annexin A2 were required 
in lung surfactant secretion [112, 118, 190, 191, 196, 214], we proposed that SNARE 
proteins and annexin A2 function cooperatively in regulating surfactant secretion, with 
annexin A2 acting as a Ca2+ sensor and mediating the final membrane fusion. In this 
study, we first determined the physical interactions between SNARE proteins and 
annexin A2 by utilizing the in vitro Glutathione S-Transferase (GST) pull-down assay 
and co-immunoprecipitation. We also identified the annexin A2 binding site of SNAP-23. 
We then investigated their functional interactions with the usage of an in vitro biological 
membrane fusion model. Collectively, our results demonstrated that SNARE proteins and 
annexin A2 are physically and functionally linked together.  
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Materials & Methods 
Reagents and chemicals: Octadecyl rhodamine B chloride (R18) was obtained from 
Molecular Probes (Eugene, OR). Maclura pomifera agglutinin gel was from EY 
Laboratories (San Mateo, CA). Fetal bovine serum (FBS), trypsin-EDTA, DMEM, Opti-
MEM, and Lipofactamine 2000 were from Invitrogen (Carlsbad, CA). Enhanced 
chemilluminescence (ECL) reagent, glutathione sepharose 4B beads were from 
Amersham Pharmacia Biotech (Arlington Heights, IL). N-Ethylmaleimide (NEM) was 
obtained from Sigma-Aldrich (St. Louis, MO). S-Nitroso-L-glutathione (GSNO) was 
from Cayman Chemicals (Ann Arbor, MI). Anti-SNAP-23 antibodies were raised using 
the synthetic peptide corresponding to C-terminal residues 199-210 (CANTRAKKLIDS) 
of rat SNAP-23 (Genmed Synthesis Inc., South San Francisco, CA). These antibodies 
were affinity-purified using peptide-conjugated beads, as previously described [190]. 
Anti-annexin A1, A4, A5, A6 antibodies, and Protein G PLUS-Agarose were from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-annexin A2 antibodies were from Santa Cruz 
Biotechnology and Zymed Laboratories (South San Francisco, CA). Anti-annexin A3 
antibody was a kind gift from Dr. J. D. Ernst of the University of California in San 
Francisco. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was 
from BD Biosciences (Palo Alto, CA). Anti-green fluorescent protein (GFP) antibody 
was from Abcam (Cambridge, MA). Anti-FLAG antibody was from Cell Signaling 
Technology (Danvers, MA). Goat anti-rabbit secondary antibody (horseradish 
peroxidase-conjugated IgG) was from Bio-Rad Laboratories (Hercules, CA). Rat anti-
mouse secondary antibody was from Jackson Immunoresearch Laboratories (West Grove, 
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PA). E. coli BL21 (DE3)pLysS was from EMD Biosciences (Novagen Brand, Madison, 
WI).   
Plasmids and Cells: The pGEX expression vectors encoding GST-tagged SNARE 
proteins were as follows [171, 235]: cytoplasmic domains of syntaxin 1A (residues 1-
265), syntaxin 2 (1-265), syntaxin 3 (1-263), and syntaxin 4 (1-272) were provided as a 
kind gift from Dr. V. M. Olkkonen (National Public Health Institute, Helsinki, Finland); 
and full-length SNAP-23 and SNAP-25 were kindly provided from Dr. A. Klip (The 
Hospital for Sick Children, Toronto, Canada). Cytosolic domains of VAMP-2 (1-94), 
VAMP-8 (1-75) and full-length Rab14 were from Dr. Richard H. Scheller of the Stanford 
University. To construct SNAP-23 deletion mutants, various fragments of SNAP-23 were 
amplified from the plasmid containing full-length SNAP-23 and inserted into the same 
expression vector. The overexpression vector for annexin A2-GFP (pE/CMV-AII-GFP) 
was constructed as described [214](Gou et al., 2004). For overexpression of SNAP-23, 
full-length SNAP-23 or SNAP-23∆CRR fragments were amplified with FLAG tag added 
at C-terminus via the 3’ primer. The mammalian two-hybrid assay kit from Stratagene 
was utilized. Full-length SNAP-23, p11 or Rab14 genes was inserted into the bait vector 
pCMV-BD, respectively. For target construct of pE/CMV-AII-NLS-AD, the GFP gene in 
pE/CMV-AII-GFP was replaced with the fragment amplified from target vector pCMV-
AD, containing SV40 nuclear localization signal, NF-κB activation domain and SV40 
polyA (nt 660-1783). All the constructs were confirmed with DNA sequencing. Cell line 
293 and A549 were from ATCC. 
Purification of bovine annexins: Annexin A1, A2 monomer and tetramer, A4, A5 and A6 
were purified from bovine lung tissue through sequential column chromatography by 
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using DEAE-Sepharose CL6B, Sephacryl S100, and Mono S columns with the method of 
Khanna et al. [236] as described previously [118].  
Preparation of alveolar type II cell lysate: Alveolar type II cells were isolated from 180-
200 gram Sprague-Dawley rats, according to the method of Dobbs et al. [237] as 
described previously [118]. Freshly isolated cells were lysed in lysis buffer (40 mM 
Hepes, pH 7.0, 100 mM KCl, 1 mM EGTA, 2 mM MgCl2, 1% NP40 and a protease 
inhibitor cocktail including 1 mM PMSF, 10 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml 
benzamidine, and 10 uM pepstatin), followed by sonication on ice for 15 seconds. The 
lysate was centrifuged at 100,000 ×g for 1 hour at 4 oC, and the supernatant was collected.  
Expression and purification of GST-tagged SNARE proteins: The GST-SNARE cDNA 
clones were transformed into E. coli BL21 (DE3)pLysS and GST recombinant proteins 
were purified. Briefly, a single colony was inoculated in Luria-Bertani medium 
containing 100 µg/ml of ampicillin. When the A660 reached 0.6-0.8, 1 mM Isopropyl β-
D-thiogalactopyranoside (IPTG) was used to induce the protein expression for 4-5 hours 
at 37 oC. The cells were harvested by low speed centrifugation and washed with cold 
phosphate-buffered saline (PBS) for three times. The cells were then sonicated and 
centrifuged at 20,000 ×g for 15 min. The cell lysate was incubated with Glutathione 
Sepharose 4B beads. The recombinant protein then was eluted with 10 mM reduced 
glutathione and stored at -80 oC. 
In vitro GST pull-down experiments: Glutathione Sepharose 4B beads were first 
incubated with 0.5% BSA to block non-specific binding for 3 hrs. 10 µl (bed volume) of 
the beads were then mixed with 0.2 nmole of GST or GST-SNARE protein in 100 µl of 
reaction volume and incubated for 4 hours at 4 oC. The beads were washed with the 
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binding buffer (40 mM Hepes, pH 7.0, 100 mM KCl, 1 mM EGTA, 2 mM MgCl2, 1% 
NP40 and varying concentrations of Ca2+) and incubated with either purified AIIt (2, 4, 8, 
16, 32, or 64 µg), or other annexins, or alveolar type II cell lysate (500 µg). Following 
end-to-end rotation at 4 oC for 4 hours, beads were washed with binding buffer for six 
times and boiled with SDS sample buffer. The soluble fractions were detected for the 
presence of annexins by Western blotting. To modify AIIt, 10 µg of AIIt was incubated 
with 1 mM N-ethylmaleimide (NEM) or 1 mM S-nitroso-L-glutathione (GSNO) in 100 
µl of 0.1 M phosphate buffer (pH 7.0) for 15 min. Samples were dialyzed against binding 
buffer to remove NEM or GSNO. The control was treated in the same way except that 
NEM and GSNO were omitted. The treated AIIt then was used for pull-down assays.  
Immunofluorescence: Freshly isolated alveolar type II cells were fixed with 4% 
paraformaldehyde for 20 minutes at room temperature. The cells were cyto-spun onto 
glass slides and stored at 4 oC until use. Immunocytochemistry was done as described 
earlier [238]. In brief, cells were permeabilized with 1% Triton X-100 and then blocked 
with 10% FBS in 50 mM PBS. The slides were then incubated overnight at 4 oC with 
monoclonal anti-annexin A2 antibodies (1:50 dilution, BD Biosciences) and polyclonal 
anti-SNAP-23 antibodies (1:100 dilution). Subsequently, they were washed and 
incubated with Alexa Fluor 488 goat anti-mouse and Alexa Fluor 568 goat anti-rabbit 
antibodies at 1:250 dilutions for 1 hour at room temperature. Finally, the slides were 
washed and mounted for fluorescence microscopy (Nikon Inc). 
Luciferase assay: 0.5 x 106 of A549 cells were seeded in 6-well plates in 2 ml of 
complete DMEM containing 10% FBS and non-essential amino acid. Transfection was 
performed at 80% cell confluence. 775 ng of total DNA (bait vector pCMV-BD-SNAP-
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23, p11 or Rab14, target vector pE/CMV-AII-NLS-AD, and report vector pFR-Luc, 250 
ng each; second reporter vector pRL-TK, 25 ng) was used. 48 hours after transfection, 
luciferase activities were measured with a dual-luciferase reporter assay system 
(Promega). In brief, cells were washed with PBS and lysed. 7 µl of lysate was mixed with 
35 µl of Luciferase Assay Reagent II (LAR II) and firefly (Photinus pyralis) luciferase 
activity was measured.  This reaction was stopped and the Renilla (Renilla reniformis) 
luciferase reaction was started simultaneously by adding 35 µl of Stop & Go Reagent to 
the same sample. The firefly luciferase activity was normalized against that of Renilla 
luciferase. The luminometer used was FLUOstar OPTIMA from BMG Biotech Inc. 
(Durham, NC). 
Co-immunoprecipitation of annexin A2 and SNAP-23: To overexpress annexin A2-GFP 
and SNAP-23-FLAG, 0.5 x 106 of 293 cells were seeded in 6-well plates in 2 ml of 
complete DMEM containing 10% FBS and non-essential amino acid. Transfection was 
performed when the cells reached 80% confluence. 500 ng of plasmid pE/CMV-annexin 
A2-GFP was mixed with 500 ng of either pE/CMV-SNAP-23-FLAG or pE/CMV-SNAP-
23∆CRR-FLAG in 50 µl of Opti-MEM. The transfection reagent Lipofectamine 2000 
was used with a DNA:reagent ratio of 1:3 (mass:volume). 48 hours after transfection, 
cells were washed with PBS, and lysed in lysis buffer (40 mM Hepes, pH 7.0, 100 mM 
KCl, 1 mM EGTA, 2 mM MgCl2, 1% NP40 and a protease inhibitor cocktail). 1.5 µl of 
anti-GFP antibody was added into 150 µl of cell lysate, and CaCl2 was supplemented to a 
final concentration of 1 mM. The mixture was then incubated at 4 oC overnight. 15 µl of 
Protein G PLUS-Agarose was added and incubated for an additional 4 hours at room 
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temperature. The resin was then washed with binding buffer for four times, and boiled 
with SDS sample buffer. The soluble fractions were detected by Western blotting. 
Western Blotting: Protein samples were fractionated on 10% SDS-PAGE and 
electrophoretically transferred to a nitrocellulose membrane. The blot was visualized with 
Ponceau S staining and blocked with 5% fat free milk in tris-buffered-saline with Tween 
20 (TTBS, 20 mM Tris-HCl, pH 7.6, 150 mM NaCl and 0.1% Tween 20). The blot was 
incubated with appropriate primary antibodies (annexin A1, 1:1000; annexin A2, Santa 
Cruz 1:500; annexin A2, Zymed 1:1000; annexin A3, 1:500; annexin A4, 1:1000; 
annexin A5, 1:1000; annexin A6, 1:1000; FLAG, 1:1000; and GAPDH, 1:4,000) at 4 oC 
overnight, and then with secondary antibody (1:5,000) at room temperature for 1 hour. 
Finally, the signal was developed with ECL and detected with VersaDoc Imaging system 
(Bio-Rad). The quantification of Western Blotting was performed by using Quantity One 
4.0.3 software (Bio-Rad).  
Isolation of Lamellar Body: Lamellar bodies were isolated from rat lung by upward 
flotation on a discontinuous sucrose gradient, as described by Chander et al. [239] and 
Chattopadhyay et al. [112]. A perfused rat lung was briefly homogenized in 1 M sucrose 
and loaded at the bottom of a sucrose gradient (0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 M). 
After centrifugation at 80,000 ×g for 3 hours, the lamellar body fraction was collected at 
the 0.4 and 0.5 M interface, and diluted to 0.24 M with cold water. Lamellar bodies were 
then spun down at 20,000 ×g and resuspended in 0.24 M sucrose containing 10 mM Tris 
and 50 mM Hepes (pH 7.0). The protein concentration of lamellar bodies was determined 
by Bio-Rad protein assay. 
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Preparation of plasma membrane: The preparation of plasma membrane from rat lung 
tissue was performed, as described previously [112]. A Sprague-Dawley rat lung was 
perfused with saline and homogenized in buffer B (10 mM Na-Phosphate, pH 7.4, 30 
mM NaCl, 1 mM MgCl2, 5 µM PMSF, and 0.32 M sucrose). Following a discontinuous 
sucrose gradient (0.5, 0.7, 0.9 and 1.2 M) centrifugation at 95,000 g for 60 minutes, the 
plasma membrane fraction was collected at the 0.9 and 1.2 M interface and diluted to 
0.32 M sucrose with cold buffer A (buffer B without sucrose). The plasma membrane 
was spun down at 120,000 ×g and resuspended in buffer B. To remove the outside-out 
plasma membrane vesicles, the plasma membrane was incubated with Maclura pomifera 
agglutinin-conjugated beads. To incorporate R-18 into the inside-out plasma membrane 
vesicles, 1 µl of a 20 mM stock solution (in ethanol) of R-18 was injected by using a 10-
µl syringe to 300 µg protein of plasma membrane in 300 µl of buffer B by vortexing. The 
mixture was incubated for 30 minutes by end-to-end rotation at room temperature, and 
excessive R-18 was removed by dialysis against 3 liters of buffer B.  
Annexin A2 tetramer-mediated fusion assay: The fusion between lamellar bodies and the 
plasma membrane was measured by monitoring the fluorescence changes of R-18, as 
described by Hoekstra et al. [240] and Chattopadhyay et al. [112]. R-18 was incorporated 
into the plasma membrane at a self-quenching concentration. Fusion of the plasma 
membrane with unlabeled lamellar bodies resulted in the dilution of R-18, due to the 
increased surface area. The relief of the self-quenching of R-18 led to the increase in 
fluorescence. In our standard assay, 5 µg protein of plasma membrane was mixed with 10 
µg protein of lamellar bodies in 1 ml of Ca2+-EGTA buffer (40 mM Hepes, pH 7.0, 100 
mM KCl, 1 mM EGTA, 2 mM MgCl2, and 1 mM Ca2+) at 37 oC with a continuous 
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stirring. A basal reading was recorded for 2 minutes, and 10 µg of annexin A2 tetramer 
was added to initiate the fusion. After an additional 6 minutes of recording, 0.1% (v/v) 
Triton X-100 was added to achieve the maximal fluorescence. Fusion was calculated as a 
percentage of the maximal fluorescence. To investigate the functional relationship 
between SNAREs and annexin A2, the plasma membrane was incubated with anti-
SNAP-23 antibodies at room temperature. It was then mixed with lamellar bodies and 




SNAP-23 binds with annexin A2 in vitro 
To explore the relationship between SNARE proteins and annexin A2, we 
investigated their physical interactions by using GST pull down assay. SNAP-23, 
syntaxin 2, and VAMP-2 are the major SNARE isoforms in alveolar type II cells [190, 
241] and were tested. We used the same amount (0.2 nmoles) of GST-SNARE fusion 
proteins and varying doses of purified AIIt in the presence of 1 mM Ca2+. As shown in 
Fig. II.1 A and B, SNAP-23 had a strong binding with purified AIIt. This binding was 
AIIt-dose dependent. The increase in binding was unlikely due to the variation of 
loadings, pull down or transfer of GST-SNAP-23, since Ponceau S staining showed the 
same amount of GST-SNARE fusion proteins after electrophoretic transferring. In 
contrast to SNAP-23, syntaxin 2, VAMP-2, or GST control did not show binding with 
purified AIIt except that a weak binding was noted at very high doses of AIIt. We also 
tested the ability of other SNARE isoforms to bind with AIIt under the same conditions 
as above with 8 µg of purified AIIt. As shown in Fig. II.1 C, SNAP-25, the neuronal 
isoform of SNAP-23, also had a very strong binding, while syntaxin 1A, 2, 3, 4, and 
VAMP-2, 8 did not have significant binding. 
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Fig. II.1 SNAP-23 binds with purified annexin A2 in a dose-dependent manner 
(A) Glutathione sepharose beads were incubated with 0.2 nmole of GST-SNAP-23, 
GST-syntaxin 2, GST-VAMP-2 or GST, followed by the incubation with various 
amounts of purified annexin A2 tetramer (AIIt, 2-64 µg) in the presence of 1 mM Ca2+. 
The bound annexin A2 was detected with Western Blotting. GST-SNARE fusion proteins 
were stained with Ponceau S. (B) Quantitation of the binding. Each band was quantified 
by densitometry. A linear range was determined by using purified AIIt. The background 
binding with GST was subtracted from those of GST-SNARE proteins. The results were 
expressed as a percentage of the maximal binding (the binding of GST-SNAP-23 with 64 
µg of AIIt). Data shown are means ± SE (n=3 independent experiments). (C) The binding 
of AIIt with other SNAREs. AIIt (8 µg) was incubated with glutathione sepharose beads 
pre-incubated with 0.2 nmole of GST-syntaxin 1A, 2, 3, 4, GST-SNAP-23, 25, or 
VAMP-2, 8. The bound annexin A2 was detected with Western blotting.  
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Binding between SNAP-23 and annexin A2 is Ca2+-dependent 
Most of the activities of annexin A2, including binding to phospholipids and 
mediating membrane fusion, are Ca2+-dependent. We further tested the Ca2+ requirement 
for the binding of annexin A2 and SNAP-23. As shown in Fig. II.2, AIIt did not exhibit 
any binding to SNAP-23 at ≤ 1 µM Ca2+. There was weak binding at 10 µM – 100 µM 
Ca2+. The binding was increased significantly when the Ca2+ concentration reached 500 
µM. 
 
SNAP-23 does not bind with other annexin isoforms 
The experiments above were performed by using purified bovine annexin A2 
tetramer. Annexin A2 exists as a monomer without partner p11 as well. To find out 
whether p11 is required for the binding, we repeated the pull-down experiments with 
purified annexin A2 monomer. The result showed that annexin A2 monomer bound with 
GST-SNAP-23 in the presence of 1 mM Ca2+, while GST had no binding (Fig. II.3A). To 
investigate the binding specificity of SNAP-23, other members of annexin family were 
tested for the binding with GST-SNAP-23. Same amounts (0.2 µmole) of purified 
annexin A1, A4, A5 and A6 were incubated with GST-SNAP-23 in the presence of 1 mM 
Ca2+. As shown in Fig. II.3A, none of these annexins had binding with GST-SNAP-23. 
Furthermore, we performed the pull-down experiments with rat alveolar type II cell 
lysate. The results showed that endogenous annexin A2 also bound with GST-SNAP-23 
in a Ca2+-dependent manner. The GST control did not bind with annexin A2. Neither 
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Fig. II.2 Binding between SNAP-23 and annexin A2 tetramer is Ca2+-dependent  
GST-SNAP-23 (0.2 nmole) pre-bound to glutathione sepharose beads was incubated 
with 8 µg of AIIt at various concentrations of Ca2+. GST-SNAP-23 was stained with 
Ponceau S (A, upper panel) and annexin A2 was detected with Western Blotting (A, 
lower panel). In (B), the bindings were quantitated by densitometry, and the results were 
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Fig. II.3 SNAP-23 does not bind with other annexins  
(A) Glutathione sepharose beads were incubated with 0.2 nmole of GST-SNAP-23 
or GST, followed by the incubation with 0.2 nmole of various purified annexins (annexin 
A1, A2 monomer, A4, A5, and A6) in the presence of 1 mM Ca2+. The bound annexins 
were probed with the corresponding antibodies. 100 ng of each annexin protein was used 
as a positive control for Western blotting. (B) Freshly isolated rat alveolar type II cells 
were lysed and centrifuged at 100,000 ×g for one hour. Glutathione sepharose beads 
bound with GST-SNAP-23 or GST (0.2 nmole) were incubated with the cytosol (500 µg 
of total protein) in the presence or absence of 1 mM Ca2+. GST-SNAP-23 and GST were 
stained with Ponceau S. Annexin A2, annexin A3 and GAPDH were detected with 
Western blotting. Type II cell cytosol (10 µg of protein) was used as a positive control for 
the Western blotting. 
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Chemical modification of annexin A2 inhibits its binding with SNAP-23 
We have previously shown that the modification of its cysteine residues by NEM or 
GSNO reduced AIIt-mediated fusion [112, 242]. As shown in Fig. II.4, the binding 
between AIIt and SNAP-23 were inhibited after the treatment of AIIt with 1 mM NEM 
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Fig. II.4 Modification of annexin A2 inhibits its binding with SNAP-23  
AIIt (8 µg) was treated with 1 mM NEM or 1 mM GSNO for 15 minutes in 100 µl 
of 0.1 M phosphate buffer, pH 7.0. After the incubation, the mixture was dialyzed against 
binding buffer overnight to remove NEM or GSNO. The binding assay was performed 
with 8 µg AIIt, 0.2 nmole of GST-SNAP-23 and 1 mM Ca2+. The results were expressed 
as a percentage of the untreated control. Data shown are means ± SE. **P< 0.01 versus 
control (student t test, n=3). 
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SNAP-23 is co-localized with annexin A2 in alveolar type II cells 
To examine whether SNAP-23 and annexin A2 are co-localized in intact cells, we 
performed dual-labeling experiments on alveolar type II cells using anti-SNAP-23 and 
anti-annexin A2. As shown in Fig. II.5, the staining patterns of SNAP-23 and annexin A2 
overlapped, indicating that they may interact in the cells. 
 
 
Fig. II.5 Co-localization of SNAP-23 and annexin A2 
Alveolar type II cells were double-labeled with anti-SNAP-23/Alexa Fluor 488 anti-
mouse and anti-annexin A2/Alexa Fluor 568 anti-rabbit antibodies (upper panels). The 
controls without primary antibodies are shown in lower panels. Scale bar: 10 micron. 
 43
SNAP-23 interacts with annexin A2 as determined by mammalian two-hybrid assay 
To investigate the interaction of annexin A2 and SNAP-23 in vivo, we utilized a 
mammalian two-hybrid system (Stratagene). Annexin A2 and SNAP-23 gene were fused 
to NF-κB activation domain (AD) and GAL4 DNA binding domain (BD), respectively, 
resulting plasmids pCMV-AD-AII and pCMV-BD-SNAP-23. However, no fusion protein 
was expressed from pCMV-AD-AII (data not shown). This was because the NF-κB 
activation domain was placed at the N-terminus of annexin A2. We therefore constructed 
a new vector in which the NF-κB activation domain was placed at the C-terminus of 
annexin A2. This was accomplished by sub-cloning the DNA fragment, containing SV40 
nuclear localization signal and NF-κB activation domain, into annexin-GFP expression 
vector pE/CMV-AII-GFP. Annexin A2 binding partner p11 was fused with BD as a 
positive control for the interaction. Co-transfection of the resulting pE/CMV-AII-NLS-
AD and pCMV-BD-p11 into 293 and A549 cells resulted in a significant increase in 
luciferase activity, indicating the interaction between annexin A2 and p11 occurred and 
this modified two-hybrid system can be used to study the interaction of annexin A2 with 
its binding partners in mammalian cells. Rab14 had no binding with annexin A2 in GST 
pull-down assay (data not shown) and was fused to BD as a negative control. As shown 
in Fig. II.6, transfection of pE/CMV-AII-NLS-AD or pCMV-BD-SNAP-23 alone showed 
only negligible activity (0.051 ± 0.007 and 0.070 ± 0.004, respectively). The luciferase 
activity was not significantly changed by co-transfection of annexin A2 with Rab14 
(0.066 ± 0.006), whereas co-transfection of annexin A2 with SNAP-23 led to a 
significant increase (0.132 ± 0.014, p<0.01) over the control, although a little lower than 

























Fig. II.6 SNAP-23 interacts with annexin A2 is determined by mammalian two-hybrid 
assay 
pCMV-BD-SNAP-23 (SNAP-23) and pE/CMV-AII-NLS-AD (AII) were co-
transfected into A549 cells. The cells were lysed 48 hours later and applied to a dual 
luciferase assay. Firefly luciferase activity was measured and quenched, followed by 
Renilla luciferase activity measurement. pCMV-BD-Rab14 was used as a negative 
control and pCMV-BD-p11 was a positive control. Data were expressed as a ratio of 
Firefly/Renilla luciferase activity and shown as means ± SE. **P< 0.01 versus negative 




Cysteine-rich region of SNAP-23 is required for the binding with annexin A2: 
SNAP-23 has two SNARE motifs at its N- and C- termini and a cysteine-rich region 
(CRR) between them. To identify the domains of SNAP-23 essential for its binding with 
annexin A2, we constructed various SNAP-23 deletion mutants (Fig. II.7A). The 
recombinant GST fusion proteins were expressed in E. coli and purified. The purity of 
these recombinant proteins was shown in Fig. II.7B. The N76 mutant has a deletion of the 
C-terminal 77-211 amino acids (CRR and the C-terminal SNARE motif). The ability of 
the N76 mutant to bind with annexin A2 tetramer was almost abolished in comparison 
with that of full-length SNAP-23 (7.5 ± 5.9%). However, the mutant N88, which retains 
the additional 12-amino acid CRR, had a binding of 95.4 ± 16.8% (Fig. II.7C, D). The 
deletion of C-terminal SNARE motif (∆C71) had no significant effect on the binding. 
Interestingly, the ∆C23 mutant, which is equivalent to the botulinum neurotoxin (BoNT) 
E cleavage, slightly increased the binding (128.0 ± 32.0%). However, the ∆C9 mutant, 
which is equivalent to the BoNT A cleavage, showed a decreased binding (37.9 ± 13.0%). 
The deletion of N-terminal 18, 32 amino acids or the N-terminal SNARE motif (1-76 
amino acids) renders the recombinant proteins prone to degrade. However, these mixtures 
containing intact and partially-degraded recombinant proteins still bound to annexin A2 
(data not shown). We also tested the ability of annexin A2 monomer to bind with these 
mutants as well and the same binding pattern as annexin A2 tetramer was observed (data 
not shown). To further confirm the importance of the cysteine-rich region, we deleted 
CRR domain from full-length SNAP-23 (∆CRR) (Fig. II.8A). Similar to N76 mutant, the 
∆CRR mutant failed to bind with annexin A2 (6.1 ± 2.8%) (Fig. II.8C, D). There are five 
cysteine residues within the CRR domain. Using site-directed mutagenesis, we 
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substituted one (C83S), two (C85,87S) and three cysteine residues (C83,85,87S) with 
serine in the N88 mutant. The substitution of cysteine residues in the mutant N88 
dramatically decreased its binding with annexin A2 from 95.4 ± 16.8% (N88) to 39.9 ± 
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. II.7 Cysteine-rich region of SNAP-23 is required for the binding with annexin A2  
and 
s on the fusion 
binant 
roteins as visualized by Coomassie Brilliant Blue R-250 staining. (C) 0.2 nmole of 
ST-tagged SNAP-23 mutant protein was bound to glutathione sepharose beads and was 
cubated with 8 µg of AIIt and 1 mM Ca2+. Recombinant proteins were stained with 
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Fig
(A) Diagrammatic representations of SNAP-23 mutants. The top diagram represents 
full-length SNAP-23. The cysteine-rich region (CRR) between residues 76 
88 (crossed) and two SNARE motifs (dotted) are shown. The number





Ponceau S (upper panel) and annexin A2 was detected with Western Blotting (lower 
pane
 
      
 
l). (D) The bindings were quantitated by VersaDoc Imaging system (Bio-Rad), and 
the results were expressed as a percentage of full-length SNAP-23 recombinant protein. 
Data shown are means ± SE. *P< 0.05, **P< 0.01 versus Full-length (student t test, n=3 
independent experiments).  
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Fig. II.8 Cysteine residues in cysteine-rich region of SNAP-23 are required for binding 
between SNAP-23 and annexin A2  
(A ms show full-length SNAP-23 with the CRR deletion (ΔCRR) and





in the presence of 1 mM Ca2+. Recombinant proteins were stained with Ponceau S (upper 
panel) and annexin A2 was detected with Western Blotting (lower panel). (D) The 
bind
 type, but not the CRR deletion mutant was co-precipitated 
ith annexin A2. The control pre-immune serum did not pull down annexin A2, SNAP-
 our in vitro study.   
 
ings were quantitated by VersaDoc Imaging system (Bio-Rad), and the results were 
expressed as a percentage of full-length SNAP-23 recombinant protein. Data shown are 
means ± SE. *P< 0.05, **P< 0.01 versus Full-length or N88 (student t test, n=4 
independent experiments).    
 
SNAP-23 is co-immunoprecipitated with annexin A2 
To investigate the interaction of annexin A2 and SNAP-23 in cells, we co-expressed 
annexin A2-GFP fusion protein with FLAG-tagged SNAP-23 wild type or SNAP-23 
∆CRR mutant in 293 cells. Immunoprecipitation was performed by using anti-GFP 
antibody. As shown in Fig. II.9, a similar amount of annexin A2-GFP fusion protein was 
immunoprecipitated from SNAP-23 wild type- and SNAP-23 ∆CRR- expressed cells. 
However, only SNAP-23 wild
w
23 or SNAP-23 ∆CRR. The results are consistent with
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Annexin A2-GFP and FLAG-tagged SNAP-23WT or SNAP-23ΔCRR fusion 
proteins were co-expressed in 293 cells, and cells were lysed 48 hours after transfection. 
Annexin A2-GFP was immunoprecipitated with anti-GFP antibody (α-GFP) or pre-
immune serum. The immunoprecipitates were
FLAG antibodies.  The 
blot shown is a representative from 3 independent experiments. 
 
dy was raised against C-
rminal residues 199-210 of rat SNAP-23.  It recognized SNAP-23, but not SNAP-25 or 
P-23 antibody inhibited the fusion 
in a 
 probed with anti-annexin A2 and anti-
 The cell lysate was used as a positive control for western blotting.
Anti-SNAP-23 antibody inhibits AIIt-mediated fusion 
To investigate the functional interaction of annexin A2 and SNAP-23, we utilized an 
in vitro biological membrane fusion model, in which the isolated plasma membrane and 
lamellar bodies were induced to fuse by purified annexin II tetramer [112]. Because 
SNAP-23 showed a direct interaction with annexin A2, we blocked SNAP-23 on the 
plasma membrane with an affinity-purified antibody and tested AIIt-mediated fusion 
between lamellar bodies and the plasma membrane. This antibo
te
syntaxins 1-4 [190]. As shown in Fig. II.10, anti-SNA
dose-dependent manner, while rabbit IgG did not show any effects. These results 
indicated that SNAP-23 was required for AIIt-mediated fusion between lamellar bodies 
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Fig. II.10 Anti-SNAP-23 antibody inhibits AIIt-mediated fusion between lam
and the plasma membrane 
IgG (礸 )

























Five µg protein of R-18-labeled plasma membrane were incubated with various 
amounts of anti-SNAP-23 antibody or rabbit IgG control at room temperature for 30 min 
and then mixed with 10 µg protein of lamellar bodies in 1 ml of Ca2+-EGTA buffer (1 
mM free Ca2+). Ten µg of AIIt were added to initiate the fusion. The fusion was 
expressed as a percentage of the maximal fluorescence (Imax), achieved by adding 0.1% 
Triton X-100. (A) A representative of the fusion curves. (B) Data were expressed as a 
< 0.01 versus control (student t test, n=3). 
percentage of the control (the fusion content during 6 min incubation) and shown as 




SNARE proteins play an important role in intracellular vesicular trafficking events 
in eukaryotic cells, and are required for lung surfactant secretion from alveolar type II 
cells. In this study, we provided evidence for the physical and functional interactions 
between annexin A2 and SNAP-23. Our results indicated that annexin A2 may interact 
with SNAP-23, functioning as a Ca2+ sensor and/or fusogenic protein.  
Many proteins have been reported to interact with SNARE proteins, thus regulating 
and fine-tuning the processes of intracellular transportation. For example, the interaction 
of n-Sec1 and syntaxin 1 [243], Snapin and SNAP-23 [244], or synaptophysin and 
VAMP-2 [245] modulates the assembly/disassembly of SNARE complex. Rabphilin 
directly interacts with SNAP-25 via its C2B domain [246]. Expression of the rabphilin 
mutant lacking the C2B domain in PC12 cells decreases the number of docked vesicle or 
fusing at the plasma membrane. Synaptotagmin I binds to SNAP-25 in a Ca2+-dependent 
manner and the cleavage of the C-terminus of SNAP-25 by BoNT E abolished this 
binding [247]. Functionally, synaptotagmin I stimulates SNARE-mediated membrane 
fusion in the presence of Ca2+ [227]. Among all of the SNARE partners reported, it 
appears that only synaptotagmin I requires Ca2+ for its interaction. However, 
synaptotagmin I-depleted neurons still can release neurotransmitter with different kinetics 
[228], suggesting that other additional Ca2+-binding proteins, that behave as Ca2+ sensors, 
may exist.  
Annexins are a superfamily of Ca2+-dependent phospholipid binding proteins. Each 
annexin has a conserved C-terminal core domain, which harbors the Ca2+/membrane 
binding sites. This feature confers annexins as potential Ca2+ sensors, monitoring the 
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changes in cytoplasmic Ca2+ concentration. The sequential conformational changes upon 
the binding with Ca2+ may regulate their functions. Annexin A7 has been reported to 
work as a Ca2+ sensor in exocytotic secretion in chromaffin cells [248]. The insertion of 
the N-terminal domain of annexin A1 into its C-terminal core domain in the absence of 
Ca2+ represents the inactive form of the protein, while the conformational switch in the 
presence of Ca2+ may trigger the exposure of some domains for additional interactions 
[249]. Besides the conserved C-terminal domain, annexin A2 contains the 
phosphorylation sites and p11 binding sites at the N-terminal domain. Our data showed 
that annexin A2 specifically interacted with SNAP-23 in a Ca2+-dependent manner, 
suggesting that annexin A2 may be a candidate of the Ca2+ sensor. This Ca2+ requirement 
may be due to a similar exposure of binding site of annexin A2 induced by its binding 
with Ca2+. Our previous study has demonstrated that only annexin A2, but not annexin 
A1, A3, A4, A5, or A6 is able to promote the fusion of lamellar bodies with the plasma 
membrane [112] and to reconstitute surfactant secretion in the permeabilized type II cells 
[118]. In this study, we also found that only annexin A2, but not other annexins interacted 
with SNAP-23. This suggests that the specific interaction between annexin A2 and 
SNAP-23 may be functionally relevant.  
In this study, the deletion of various segments of SNAP-23 identified cysteine-rich 
region as the binding site of SNAP-23 to annexin A2. There are no reports about direct 
interactions of SNAP-25/23 with their possible regulatory proteins within this region so 
far.  Although the cysteine-rich region is the site for palmitoylation and may facilitate the 
association of SNAP-25/23 to the plasma membrane [155, 157, 159], an alternative 
mechanism for SNAP-25/23 association with membrane via the binding of syntaxin has 
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been proposed [250-252]. Therefore, the cysteine-rich region is still likely available for 
the interaction with additional proteins in vivo. The cysteine residues play a role in fine-
tuning the affinities of SNAP-25/23 for plasma membrane and the mutations of these 
residues only restore the exocytosis to different extents in a permeabilized cell system 
[253, 254]. Another report has shown that the cysteine residue mutant of SNAP-25 still 
can form SDS-resistant complex with syntaxin 1A and VAMP-2. However, this complex 
can not be disrupted by NSF. Furthermore, these mutants are not able to rescue the 
exocytosis [251]. SNAP-23 has five cysteine residues within this region. The mutation of 
cysteine residue at 83 of SNAP-23 resulted in a significant decrease in its binding to 
annexin A2, and the mutations of three cysteine residues (83,85,87) almost abolished the 
binding. These results suggest that the cysteine residues of SNAP-23 may control its 
interaction with annexin A2 in the process of exocytosis. 
BoNT A and BoNT E cleave the C-terminal 9 and 23 amino acids of SNAP-23, 
respectively. Over-expression of the SNAP-25 mutant ∆C9 decreases the fast component 
of the exocytotic burst in bovine chromaffin cells even though the over-expressed mutant 
still can assemble into SNARE complexes in vivo [255]. Interestingly, deletion of the C-
terminal 9 amino acids, but not the 23 amino acids markedly reduced its binding with 
annexin A2.  The reason for this is unclear, but could be due to the different 
conformational changes caused by the two deletions. 
By using a modified mammalian two-hybrid system, we analyzed the interaction in 
vivo, and the annexin A2 binding partner p11 was used as the positive control. We first 
tried 293 cell line originated from kidney. Unlike the positive control p11, co-transfection 
of SNAP-23 with annexin A2 only yielded negligible luciferase activity as negative 
 57
control (Data not shown). We then used the lung-originated cell line A549, in which 
significant increase in luciferase activity was observed with co-transfection of SNAP-
23/annexin A2. This suggests that some cell specific factors, which may exclusively 
required in processes in lungs, facilitated that interaction. The luciferase activity of 
SNAP-23/annexin A2 was lower than that of p11/annexin A2, which may reflect the Ca2+ 
dependence of the interaction between SNAP-23 and annexin A2.  
To carry out the functional study, we used a specific antibody against the C-terminal 
last 11 amino acids of rat SNAP-23 to block its interaction with annexin A2. This 
antibody recognizes SNAP-23 specifically and inhibits surfactant secretion in the 
permeabilized alveolar type II cells [190]. In this study, when the plasma membrane was 
pre-incubated with the anti-SNAP-23 antibody, AIIt-mediated fusion of lamellar bodies 
with the plasma membrane was decreased. One possible reason is that the antibody 
blocks the direct interaction of SNAP-23 and annexin A2. However, we can not rule out 
the possibility that the spatial hindrance from the binding of antibody interferes the 
formation of functional SNARE complexes between lamellar bodies and the plasma 
membrane.  
In summary, annexin A2 may function as a Ca2+ sensor and/or a fusogenic protein 
via its interaction with SNAP-23 in the surfactant secretion of alveolar type II cells. 
Annexin A2 has been reported to be involved into the Ca2+-evoked exocytosis in 
chromaffin cells [194, 197]. Since annexin A2 also binds with SNAP-25, this interaction 
may not be unique to alveolar type II cells and annexin A2 may function in a similar way 
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Characterization of VAMP Proteins in Alveolar Type II Cells 
 
Abstract 
Lung surfactant is crucial to reduce the surface tension at alveolar space, thus 
preventing alveoli from collapse. Lung surfactant is synthesized in alveolar epithelial 
type II cells and stored in lamellar bodies before being released via the fusion of lamellar 
bodies with the apical plasma membrane. The soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors (SNARE) play an essential role in membrane fusion and we 
have previously demonstrated the requirement of t-SNARE proteins, syntaxin 2 and 
SNAP-23, in regulated surfactant secretion. Here, we characterized the distribution of 
vesicle-associated membrane proteins (VAMPs) in rat lung and alveolar type II cells. 
VAMP-2, 3 and 8 were shown to be present in type II cells at both mRNA and protein 
levels. VAMP-2 and -8 were enriched in lamellar body fraction. Immunochemistry 
studies indicated that VAMP-2 is co-localized with the lamellar body marker protein. 
This study characterized the expression and distribution of VAMPs in lung and type II 
cells and suggests that VAMP-2 may be the v-SNARE involved in regulated surfactant 
secretion.  
 
Key Words: SNARE, VAMP, membrane fusion, lung surfactant, exocytosis 
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Introduction 
Lung surfactant forms a monolayer at air-liquid interface in alveoli to reduce the 
surface tension, thus preventing alveoli from collapse. Surfactant is composed of 
phospholipids and surfactant proteins, and most of the components are synthesized in 
endoplasmic reticulum in alveolar epithelial type II cells and stored in the specified 
organelles, lamellar bodies. The secretion of surfactant is a highly regulated process, 
including the translocation, docking and fusion of lamellar bodies to the apical plasma 
membrane, and eventually the release of the contents into alveolar lumen. Our previous 
studies have demonstrated the involvement of annexin A2, soluble N-ethylmelaimide-
sensitive fusion protein attachment protein receptor (SNARE) and some other regulatory 
factors in the secretion of lung surfactant [190, 191, 214]. However, the precise 
underlying mechanism is still not clear and needs further investigation. 
SNAREs are a protein family, which exist ubiquitously in eukaryotic cells and play 
a crucial role in membrane targeting, docking, and fusion [132, 137, 217-219]. SNARE 
proteins contain the characteristic coiled-coil domains, termed as SNARE motifs, which 
can form a trans-SNARE complex in two adjacent membranes to pull the membranes into 
close apposition, thus leading to membrane fusion [220]. There are two classes of 
SNARE proteins according their localizations in the cell. The vesicle SNARE (v-
SNARE), vesicle associated membrane protein (VAMP), is located on the membrane of 
secretory vesicles, while the target SNAREs (t-SNARE), such as syntaxin and SNAP-
25/SNAP-23, are located on the plasma membrane. VAMP-2 has been extensively 
studied in neurons and has been shown to play a critical role in Ca2+-triggered fusion of 
synaptic vesicles with the presynaptic membrane. VAMP-2 is also involved in regulating 
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secretion in other cells, such as adipocytes and pancreatic β-cells. We have previously 
found that t-SNARE proteins, syntaxin 2 and SNAP-23, are required in lung surfactant 
secretion [190]. Here, we attempted to identify the v-SNARE required in this process. We 
demonstrated the presence of VAMP-2, 3, and 8 in alveolar type II cells at mRNA and 
protein levels. Furthermore, VAMP-2 is localized on lamellar bodies. This study suggests 




Materials & Methods 
Reagents and chemicals: Fetal bovine serum (FBS), trypsin-EDTA and DMEM were 
from Invitrogen (Carlsbad, CA). Enhanced chemilluminescence (ECL) reagent was from 
Amersham Pharmacia Biotech (Arlington Heights, IL). Mouse anti-VAMP-2 antibody 
was from Synaptic System (Goettingen, Germany). Rabbit anti-VAMP-2 antibody was 
from Stressgen Bioreagents (Ann Arbor, MI). Rabbit anti-VAMP-3 antibody was from 
Affinity Bioreagents (Golden, CO). Rabbit anti-VAMP-8 antibody was from Abcam. 
(Cambridge, MA). Mouse anti-LB-180 antibody was from Covance (Richmond, CA). 
Goat anti-SP-C antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Goat 
anti-rabbit horseradish peroxidase (HRP)-conjugated IgG was from Bio-Rad Laboratories 
(Hercules, CA). Rat anti-mouse HRP-conjugated IgG was from Jackson Immunoresearch 
Laboratories (West Grove, PA). Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488 
chicken anti-rabbit, Alex Fluor 546 donkey anti-goat and Alexa Fluor 568 goat anti-
rabbit antibodies were from Molecular Probe (Eugene, OR). 18S rRNA primers were 
from Ambion (Austin, TX). 
Isolation of alveolar type II cells: Alveolar type II cells were isolated from 180-200 gram 
Sprague-Dawley rats, according to the method of Dobbs et al. [237], as described 
previously [118]. 
Reverse transcription polymerase chain reaction (RT-PCR): Total RNAs were extracted 
from rat lung homogenate or freshly isolated type II cells with TRI reagent. 1 µg of total 
RNA was reverse-transcribed to cDNA by using M-MLV reverse transcriptase and 
random hexamer primers, followed by PCR amplification with gene specific primers. The 
primer sequences were as shown in Table. III.1. 18S rRNA was amplified by using 
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classic 18S rRNA primer pairs. The conditions for PCR amplification were: 95°C for 2 
min, 35 cycles of 95°C 30 sec, 55°C 30 sec, 72°C 1 min, followed by 72°C for 8 min. 
The PCR products were electrophoretically separated on 1% agarose gel. 
Table. III.1    PCR primers for VAMP gene amplification 
 
5'-AGGGACCAGAAGTTGTCAGAGT-3' VAMP-1 
GeneID: 25624 5'-GCCATCTCCATACCTCTGCA-3' 
5'-CTGGTGTGTAAGTGTCTTGGAG-3' VAMP-2 
GeneID: 24803 5'-CAGAGATTTCAGGCAGGAATTA-3' 
5'-CTGATGTGGTTTCTTTCCTAGA-3' VAMP-3 
GeneID: 29528 5'-AGGCATGTCTTCAACACTTG-3' 
5'-GAATCAGGTGGACGAAGTTAT-3' VAMP-4 
GeneID: 364033 5'-TGTTATTGTCCCAGATCTTGTT-3' 
5'-CAGACCAAGTGACGGAAATC-3' VAMP-5 
GeneID: 89818 5'-TCCACTCGGAAGAAAGATGA-3' 
5'-GGATTGTGTATCTTTGCATCA-3' VAMP-7 
GeneID: 85491 5'-TCTATCAGCAATTCTAGCCTTT-3' 
5'-GAAATGACCGAGTCAGGAAC-3' VAMP-8 
GeneID: 83730 5'-CGTAGCAAAGAGTATGATGAGG-3' 
 
Isolation of Lamellar Body: Lamellar bodies were isolated from rat lung by upward 
flotation on a discontinuous sucrose gradient, as described by Chander et al. [239] and 
Chattopadhyay et al. [112]. A perfused rat lung was briefly homogenized in 1 M sucrose 
and loaded at the bottom of a sucrose gradient (0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 M). 
After centrifugation at 80,000 ×g for 3 hours, the lamellar body fraction was collected at 
the 0.4 and 0.5 M interface, and diluted to 0.24 M with cold water. Lamellar bodies were 
then spun down at 20,000 ×g and resuspended in 0.24 M sucrose containing 10 mM Tris 
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and 50 mM Hepes (pH 7.0). The protein concentration of lamellar bodies was determined 
by Bio-Rad protein assay. 
Preparation of the plasma membrane: The preparation of the plasma membrane from rat 
lung tissue was performed as described previously [112]. A Sprague-Dawley rat lung was 
perfused with saline and homogenized in buffer B (10 mM Na-Pi, pH 7.4, 30 mM NaCl, 
1 mM MgCl2, 5 µM PMSF, and 0.32 M sucrose). Following a discontinuous sucrose 
gradient (0.5, 0.7, 0.9 and 1.2 M) centrifugation at 95,000 g for 60 minutes, the plasma 
membrane fraction was collected at the 0.9 and 1.2 M interface and diluted to 0.32 M 
sucrose with cold buffer A (buffer B without sucrose). The plasma membrane was spun 
down at 120,000 ×g and resuspended in buffer B. 
Western Blotting: Protein samples were fractionated on 12% SDS-PAGE and transferred 
to a nitrocellulose membrane. The membrane was blocked with 5% fat free milk in tris-
buffered-saline with Tween 20 (TTBS, 20 mM Tris-HCl, pH 7.6, 150 mM NaCl and 
0.1% Tween 20). The membrane was then incubated with appropriate primary antibodies 
(VAMP-2, Stressgen, 1:1000; VAMP-2, Synaptic System, 1:5000; VAMP-3, 1:500; 
VAMP-8, 1:500) at 4 oC overnight, and then with secondary antibody (1:2500) at room 
temperature for 1 hour. Finally, the signal was developed with ECL reagents. 
Immunocytochemistry: Freshly isolated alveolar type II cells were cultured on cover slips 
overnight and then fixed with 4% paraformaldehyde for 20 minutes at room temperature. 
Immunocytochemistry was done as described earlier [238]. In brief, cells were 
permeabilized with 1% Triton X-100 and then blocked with 10% FBS in 50 mM PBS. 
The slides were then incubated overnight at 4°C with anti-LB-180 antibody (1:1000 
dilution) and anti-VAMP-2 (Stressgen) or VAMP-8 antibodies (1:100 dilution). 
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Subsequently, they were washed and incubated with Alexa Fluor 488 goat anti-mouse 
and Alexa Fluor 568 goat anti-rabbit antibodies at 1:250 dilutions for 1 hour at room 
temperature. Finally, the slides were washed, mounted and examined with a fluorescence 
microscope (Nikon Inc). 
Immunohistochemistry: Immunohistochemistry was performed as described earlier [238]. 
The rat lungs were perfused with PBS and lavaged with normal saline. Lungs were then 
fixed with 4% paraformaldehyde. Paraffin-embedded lungs were then sectioned (2 µm) 
and placed on glass slides (Fisher Scientific, Pittsburgh, PA). The slides were de-
paraffinized with xylene and re-hydrated with graded alcohol and PBS. Inactivation of 
endogenous peroxidase by incubating slides with 4% hydrogen peroxide and antigen 
retrieval was done by boiling the slides in citrate buffer (10 mM disodium citrate, pH 6.0, 
and 0.05% Tween-20) for 20 minutes. The sections were permeablized with 1% Triton 
X-100 and blocked with 10% donkey serum in 50 mM PBS. They were then incubated 
overnight at 4 oC with anti-SP-C antibody (1:100 dilution) and anti-VAMP-2 (Stressgen) 
or VAMP-8 antibodies (1:100 dilution). Subsequently, they were washed and incubated 
with Alexa Fluor 488 chicken anti-rabbit and Alexa Fluor 546 donkey anti-goat 
antibodies at 1:250 dilutions for 1 hour at room temperature. Finally, the slides were 




VAMP genes are expressed in lung and alveolar type II cells:  
There are seven members in VAMP family. We utilized RT-PCR method to 
examine the expression pattern of VAMP genes in alveolar type II cells. Specific primer 
pairs were designed and gene fragments of different VAMP isoforms were amplified 
from rat lung and highly-purified alveolar type II cells. Brain was used as a reference. As 
shown in Fig. III.1, most of the VAMP isoforms were expressed in type II cells. VAMP-2 
mRNA was observed both in lungs and type II cells. High expressions of VAMP-3 and 
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Fig. III.1 RT-PCR amplification of VAMP isoform genes in alveolar type II cells.  
Total mRNA was extracted from whole lung tissue (L) and freshly isolated alveolar type 
II cells (> 95% purity, T2) and brain (B). After reverse-transcription with random 
hexamer primers, VAMP isoform genes were amplified with specific primers for 35 
cycles with standard PCR protocols. 18S rRNA was used for normalization. PCR 
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products were electrophoretically separated on 1% agrose gels. A reaction without cDNA 
template was used as negative control (-’ve).  
 
VAMP proteins are expressed in lamellar body fraction:  
To explore the distribution of VAMP proteins in alveolar type II cells, we utilized 
Western Blotting method to examine the different fractions of type II cells. When 
polyclonal anti-VAMP-2 antibodies (Stressgen) were used, in addition to the band 
expressed in brain (18 kDa), there is another band for VAMP-2 with a lower molecular 
weight [Fig. III.2 VAMP-2 (1)]. In lung tissue, type II cells, lamellar body fraction and 
the plasma membrane, this lower band was dramatically enriched in lamellar body 
fraction. When monoclonal anti-VAMP-2 antibodies (Synaptic System) were used, only 
the 18 kDa band was observed [Fig. III.2 VAMP-2 (2)]. VAMP-8 was also detected in 
both lamellar body and the plasma membrane factions. VAMP-3 was mainly present in 
the plasma membrane fraction and was not detected in lamellar body fraction. 






Fig. III.2  The expression of VAMP proteins in alveolar type II cells.  
Freshly isolated type II cells (T2), lung tissue homogenate (L), lamellar body fraction (LB) 
and the plasma membrane fraction (PM) isolated from lungs were lysed and same 
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amounts of total protein were separated by 12% SDS-PAGE and probed with two anti-
VAMP-2 antibodies [(1) Stressgen Inc. and (2) Synaptic System GmbH], anti-VAMP-3 
and -8 antibodies, respectively. Brain (B) was used as a reference. 
 
Localizations of VAMP-2 in lung tissue and in alveolar type II cells:  
To examine the cellular localization of VAMP-2 in lung tissue, we performed 
immunohistochemistry by dual-immunolabeling technique, using anti-SP-C (a type II cell 
marker) and anti-VAMP-2 antibodies. The signal of VAMP-2 staining was overlapped 
with that of SP-C, indicating that VAMP-2 is localized in type II cells (Fig. III.3). To 
further study the localization of VAMP-2 protein in alveolar type II cells, we performed 
dual-immunostaining of VAMP-2 and LB-180, a lamellar body marker protein, in 
isolated alveolar type II cells. VAMP-2 staining was overlapped with the staining of LB-
180 (Fig. III.4A). However, VAMP-8 showed a diffusible staining pattern and was 










Fig. III.3 VAMP-2 is localized in alveolar type II cells.  
Paraformaldehyde-fixed and Triton X-100-permeabilized lung tissue sections were 
blocked and incubated with rabbit anti-VAMP-2 and goat anti-SP-C antibodies, followed 
by incubation with Alexa 546–conjugated donkey anti-goat and Alexa 488–conjugated 













Merged Bright Field 
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Fig. III.4 VAMP-2 is localized on lamellar bodies in alveolar type II cells.  
Freshly isolated type II cells were fixed with 4% paraformaldehyde and permeabilized 
with 0.5% Triton X-100. The cells were blocked and incubated with rabbit anti-VAMP-2 
or VAMP-8 antibodies and mouse anti-LB-180 antibodies. They were then incubated 
with Alexa 546–conjugated goat anti-rabbit and Alexa 488–conjugated rabbit anti-mouse 
antibodies. A: Dual labeling of VAMP-2 and LB-180; B: Dual labeling of VAMP-8 and 





SNARE proteins play a central role in eukaryotic membrane trafficking events and 
the underlying mechanism is conserved among different spices. We have previously 
demonstrated that the t-SNAREs, syntaxin 2 and SNAP-23, are present in alveolar type II 
cells and that they are required in surfactant secretion. In this study, we have 
characterized VAMP proteins in lung tissues and type II cells. 
From the RT-PCR results, we found that various isoforms of VAMP genes are 
expressed in type II cells. There are seven members in VAMP family. VAMP-1 is highly 
homologous to VAMP-2, but has a different cellular distribution pattern. It is involved in 
calcium-dependent synaptic vesicle exocytosis [175-177]. VAMP-1 is also reported to be 
expressed in non-neuronal tissues [178], but its function is not clear. VAMP-3 is 
ubiquitously expressed and preferentially associated with early/recycling endosomes. 
VAMP-3 was reported to play an important role in platelet alpha granule secretion by 
using tetanus toxin [179], antibody [180]; and the cytoplasmic domain [181]. However, 
the reduction of VAMP-3 in transgenic mice had no effects on platelet function, 
indicating it is not essential for platelet releasing reaction in mice [182]. VAMP-7 is 
resistant to tetanus neurotoxin cleavage [183]. It is associated with the late endosome and 
involved in endocytosis and intracellular trafficking between ER and Golgi [184, 185]. 
VAMP-8 has been reported as being involved in the endocytic pathway as an 
intermediate in the fusion between early and late endosomes [186, 187]. It has recently 
been reported that VAMP-8 is required in regulated exocytosis in pancreatic acinar cells 
and platelets [188, 189]. VAMP-2 was initially identified as a v-SNARE of synaptic 
vesicles in neurons, playing an important role in synaptic vesicle exocytosis [165]. 
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VAMP-2 is also involved in regulated transporting events in non-neuronal systems, such 
as trafficking of glucose transporter-4 (GLUT-4) to the plasma membrane [170-174]. We 
found that the VAMP isoforms abundantly expressed in alveolar type II cells were 
VAMP-2, VAMP-3 and VAMP-8. 
We next examined the protein expression pattern of VAMP-2, 3 and 8 in lung and 
type II cells by Western blotting. Along a band with the same size as that in brain (18 
kDa), a band with a lower mass for VAMP-2 was consistently detected by a polyclonal 
anti-VAMP-2 antibody. The lower band was highly enriched in lamellar body fraction. 
However, we only detected the 18 kDa band by using a monoclonal anti-VAMP-2 
antibody. There are two possibilities: (1) the lower band is the degradation product of 
VAMP-2; (2) it is another VAMP isoform. The identity of the lower band is not known 
and needs further investigation. VAMP-2 was also detectable in a plasma membrane 
fraction. Immuno-staining study showed that VAMP-2 was co-localized with lamellar 
body marker, LB-180, indicating that VAMP-2 is localized on lamellar bodies. This 
association is reasonable to consider the putative role of VAMP-2 as a v-SNARE in the 
fusion of lamellar bodies with the plasma membrane. VAMP-3 was barely detected in 
lamellar bodies, but was present in type II cells. It appears to be enriched in the lung 
plasma membrane fraction. Interestingly, VAMP-8 was also expressed in type II cells but 
not restricted only on lamellar bodies. The presence of more than one VAMP isoform and 
their distinctive distribution patterns suggest that different VAMP isoforms are involved 
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Lung surfactant is a surface active material existing on the alveolar walls. It reduces 
the surface tension of alveoli and prevents alveoli from collapse. Lung surfactant is 
synthesized in alveolar epithelial type II cells and stored in specified organelles, lamellar 
bodies. Lamellar bodies are lysosome-related organelles and surfactant is released into 
alveolar space through the fusion of lamellar bodies with the plasma membrane. To better 
understand the mechanisms of surfactant secretion, we carried out proteomic analyses of 
lamellar bodies isolated from rat lungs. With the peptide mass fingerprinting by MALDI-
TOF mass spectrometry, 44 proteins were identified with high possibility data matches. 
These proteins fell into diverse functional categories: surfactant related proteins, 
membrane trafficking, calcium binding, signal transduction, structural proteins, ion 
channels, protein processing and miscellaneous proteins. This proteomic profiling of 
lamellar bodies provides a new perspective on lamellar body biogenesis and surfactant 
secretion. 
 
Key Words: Lung Surfactant, Lamellar body, Proteomics, MALDI-TOF 
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Introduction 
Lung surfactant is a surface active material. It forms a monolayer at the air-liquid 
interface and reduces the surface tension of alveoli, thus preventing alveoli from collapse. 
Deficiency of surfactant at the alveolar surface results in respiratory distress syndromes 
(RDS) in both new-borns and adults. Lung surfactant is synthesized and secreted by 
alveolar type II cells. It is mainly composed of phospholipids and surfactant proteins A, B, 
C, and D. Most components of surfactant are synthesized in endoplasmic reticulum and 
stored in the specified organelles, lamellar bodies.  
Lamellar bodies are lysosome-related, large secretory organelles with 1 to 2 μm in 
size. Similar to lysosomes, lamellar bodies contain soluble lysosomal enzymes, like acid 
phosphatase, and lysosome associated membrane proteins (LAMP) [73-75]. Lamellar 
bodies also have an acidic interior of pH about 6.1 or below [76, 77]. However, lamellar 
bodies are different from lysosomes in that they are specialized for storage and secretion 
of surfactant rather than for degradation. The principle components in lamellar bodies are 
phospholipids, which are tightly packed as concentric arrangements of bi-layer 
membranes. Secretion of surfactant involves the translocation, docking and fusion of 
lamellar bodies with the apical plasma membrane. 
The molecular mechanisms that control the exocytosis of lamellar bodies are still 
poorly understood [95, 96, 215, 216]. The recent emergence of powerful proteomic 
techniques has made it possible to profile the protein components in a specific tissue or 
subcellular organelle. To better understand the regulation of lamellar body biogenesis and 
exocytosis, we performed proteomic analysis of lamellar bodies isolated from rat lungs. 
We carried out both one-dimensional and two-dimensional gel electrophoresis, followed 
 76
by MALDI-TOF mass spectrometry. Here, we report the first proteomic profiling of 




Materials & Methods 
Reagents and chemicals: The ReadyPrep 2-D cleanup kit, ReadyPrep reduction-
alkylation kit, ReadyPrep protein extraction kit and non-linear pH 3-10 ReadyStrip IPG 
strips were from Bio-Rad Laboratories (Hercules, CA).  
Isolation of Lamellar Bodies from rat lung: Lamellar bodies were isolated from rat lungs 
by upward flotation on a discontinuous sucrose gradient, as described by Chander et al. 
[239] and Chattopadhyay et al. [112]. A perfused rat lung was homogenized in 1 M 
sucrose and loaded at the bottom of a sucrose gradient (0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 
M). After centrifugation at 80,000 ×g for 3 hours, the lamellar body fraction was 
collected at the 0.4 and 0.5 M interface, and diluted to 0.24 M with cold water. Lamellar 
bodies were then spun down at 20,000 ×g and resuspended in 0.24 M sucrose containing 
10 mM Tris and 50 mM Hepes (pH 7.0). The protein concentration of lamellar bodies 
was determined by Bio-Rad protein assay. 
One-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE): Lamellar bodies were directly lysed in 1x SDS sample buffer and fractionated on 
10% SDS-PAGE. The gel was subjected to colloidal coomassie brilliant blue staining to 
visualize protein bands described as below.  
Two-dimensional gel electrophoresis: Lamellar bodies were pretreated by using 
ReadyPrep 2-D cleanup kit before being applied to electrophoresis. In brief, 500 μg of 
LB in a final volume of 100 μl was mixed with 300 μl of precipitation agent 1 and 
incubated on ice for 15 min, followed by adding 300 μl of precipitation agent 2. The 
mixture was centrifuged at 12,000 x g for 5 min and supernatant was removed. After 
being washed with washing reagent, the pellet was air-dried at room temperature and 
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resuspended in appropriate volume of 2-D rehydration/sample buffer. Supernatant was 
stored at -80 oC or used directly for isoelectric focusing (IEF). Sample in 300 μl of 
rehydration buffer was loaded into rehydration/equilibrium tray and a 17-cm non-linear 
pH 3-10 IPG strip was placed onto the sample. The strip was overlayed with 2-3 ml of 
mineral oil and left overnight to rehydrate. The strip was transferred to focusing tray and 
subjected to IEF at 50,000V-hr in a PROTEAN IEF cell. After IEF, the strip was 
transferred and incubated in 6 ml of equilibrium buffer I and II sequentially for 10 min 
each at room temperature. The strip was then applied to SDS-PAGE at 48 mA for 4-5 hrs. 
Colloidal Coomassie Brilliant Blue Staining: After SDS-PAGE, the gel was fixed with 
40% ethanol, 10% acetic acid overnight, followed by washing with water twice for 10 
min. The colloidal coomassie brilliant staining working solution was made freshly by 
mixing 80% stock solution (0.1% coomassie brilliant blue G-250, 2% ortho-phosphoric 
acid, 10% ammonium sulfate) with 20 % methanol. The gel was stained at least overnight 
and destained with 1% acetic acid till satisfactory staining was achieved.   
Matrix Assisted Laser Desorption/Ionization - Time Of Flight Mass Spectrometry 
(MALDI-TOF MS): Acrylamide bands or spots were harvested and washed 3 times with 
400 μl of 50% acetonitrile (ACN)/25 mM ammonium bicarbonate (pH 8.0) on a rocker 
shaker for 1 hour each time. The gel pieces were then incubated with 400 μl of 100% 
ACN at room temperature for 5 min to dehydrate. The gel pieces were digested by trypsin 
and equal volume of digest and saturated matrix were mixed and analyzed by MALDI-
TOF MS using a Voyager-DE Pro MALDI-TOF MS Workstation (Applied Biosystems).  
Protein Identification Analysis: Protein identification was carried out by searching the 
peptide spectra against the Mass Spectrometry protein sequence database (MSDB) using 
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the Mascot web based search engine. The search parameters used were: taxonomy, Rattus; 
allow up to 1 missed cleavage; variable modifications, carbamidomethyl (C), oxidation 




Results and Discussion 
The lamellar bodies were isolated from rat lung based on the principle of upward 
flotation of lamellar bodies during centrifugation on a discontinuous sucrose gradient. 
This protocol was first introduced by Duck-Chong [256], and well established as 
described by Chander et al. [239] and Chattopadhyay et al. [112]. The isolated lamellar 
body fraction consists of intact lamellar bodies and large amounts of concentric 
multilamellated membrane structures [256], and contain no other organelles except for 
very low amounts of microsomes [257].  
After electrophoresis, the gels were stained with colloidal Coomassie Brilliant Blue 
dye. One-dimensional SDS-PAGE revealed more than 50 protein bands (Fig. IV.1). The 
diversity of protein components suggests that storage and secretion of surfactant may not 
be the sole function of lamellar bodies. The well-separated protein bands were harvested 
for peptide fingerprint analysis.  
Due to the complexity of protein components of lamellar bodies, we also performed 
2-dimensional PAGE to get better separation. Since lamellar bodies contain large 
amounts of lipids which could affect the electrophoresis, we treated the sample with 
acetone to remove lipid components. However, the treated sample was not able to 
dissolve. We then utilized the ReadyPrep kit from BioRad to prepare the samples. After 
IEF, proteins were separated on polyacrylamide gels. As shown in Fig. IV.2, more than 
100 protein spots were revealed. These well-separated spots were harvested for peptide 











Fig. IV.1. One-dimensional SDS-PAGE of proteins of lamellar bodies. 
Lamellar bodies were isolated from perfused rat lungs as described in materials and 
method. Approximately 100 μg of total protein were loaded for electrophoresis on 10% 
Bis-Tris polyacrylamide gels. The protein bands were visualized with Coomassie 









Fig. IV.2. Two-dimensional SDS-PAGE of proteins of lamellar bodies. 
Approximately 500 μg of total lamellar body protein was cleaned up and applied to IEF. 
The protein samples in the IPG strip were then separated by polyacrylamide gel 
electrophoresis. The protein spots were visualized with Coomassie Brilliant Blue G-250 
dye. The arrows on the top indicate the isoelectric points (pI) of the proteins. The 





To identify protein components in lamellar bodies, we utilized the powerful 
technique Matrix Assisted Laser Desorption/Ionization – Time Of Flight Mass 
Spectrometry (MALDI-TOF MS). By trypsin digestion, each protein produces a unique 
set of peptides, termed as peptide fingerprints. A MALDI-TOF instrument generates the 
unique cutting profile of a target protein, expressing it as a mass spectrum. Through 
comparing the mass spectra to databases, a target protein can be identified. Fig. IV.3. is a 
mass spectrum of one protein sample from the lamellar bodies. It matches rat annexin A2. 
 




































































































Fig. IV.3. The mass spectrum of annexin A2 by MALDI-TOF mass spectrometry. 
Peaks represent peptides detected by the instrument. X-axis is mass to charge ratio for a 
defined range of masses, representing the mass of ionized peptides. Y-axis represents the 
number of ionized peptides detected, as a percentage to the maximum value (100%).  
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The peptide spectra generated from lamellar bodies proteins were searched against 
the Mass Spectrometry protein sequence database (MSDB) using the Mascot web based 
search engine. According to the Probability Based Mowse Score, the higher score a 
protein identification has, the more likely the match is true. An example is shown in Fig. 
IV.4. protein scores greater than 56 are significant (p<0.05). The score of matched 
identification JH0819, represented by the red column, is 119. It is very likely that the 
protein sample examined is JH0819 (rat calreticulin precursor).  
 
JH08 
Fig. IV.4. An example of Mascot search result: Probability Based Mowse Score. 
The score is -10*Log10(P), where P is the probability that the observed match is a random 
event. Protein scores greater than 56 are significant (p<0.05). 
 
Table IV.1. lists the 44 proteins identified from the highly purified lamellar bodies 
using peptide mass fingerprinting. Listed for each protein include NCBI accession 
number, the number of peptides matched and percent of sequence covered, the Mowse 
scores and molecular mass. The functional classification was performed by a literature 
search in the Pubmed database. 
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Table IV. 1.  Proteins identified in lamellar bodies with MALDI-TOF MS 










Calcium binding proteins 
Annexin A1 P07150 16 42 137 38674 
Annexin A2 Q07936 16 49 129 38523 
Annexin A3 LURT3 15 45 148 36341 
Annexin A4 Q5U362 14 42 140 35871 
Annexin A5 P14668 18 52 156 35591 
Annexin A6 P48037 14 20 66 75575 
Annexin A7 Q6IRJ7 8 17 57 49987 
Calreticulin precursor AAH62395 12 24 119 47966 
 
Structural proteins 
Actin-beta ATRTC 10 31 97 41724 
Vimentin P31000 20 38 119 53569 
Myosin-9 (Nonmuscle 
myosin heavy chain 
IIa) 
Q62812 47 24 143 226066 




O35763 16 20 64 67566 
Cytokeratin 19 AAR36876 15 38 108 44609 
 
Surfactant related proteins 
Surfactant protein A 
precursor P08427 10 43 63 26272 
Surfactant protein B  Q6IN44 7 19 62 41590 
ABCA3 AAH88202 7  160 240735 
Peroxiredoxin-6  NP_446028 8 33 78 24672 
Apolipoprotein A-I 
precursor AAH89820 10 35 84 30043 
Apolipoprotein A-IV AAH91159 16 39 122 44429 
Lysosome membrane 




sector ATPase alpha 
chain precursor 
J05266 12 29 57 58790 
F1-ATPase beta chain  1MABB 10 32 83 49043 
Unnamed protein 
product 
CAF05438 20 14 113 146309 
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Membrane traffic 
Ehd1 AAH82030 11 20 65 60565 
Annexin A1 P07150 16 42 137 38674 
Annexin A2 Q07936 16 49 129 38523 
Annexin A3 LURT3 15 45 148 36341 
Annexin A4 Q5U362 14 42 140 35871 
Annexin A5 P14668 18 52 156 35591 
Annexin A6 P48037 14 20 66 75575 
Annexin A7 Q6IRJ7 8 17 57 49987 
Actin-beta ATRTC 10 31 97 41724 
  
Protein processing 
Serpinh1 protein Q5RJR9 7 18 56 46532 
Dipeptidyl peptidase IV 
membrane-bound form 
precursor 
A39914 15 20 85 90869 
Alpha-1-antitrypsin 




protein kinase kinase 1 
interacting protein 1 
AAH86353 6 57 65 13571 
Rho GDP dissociation 
inhibitor (GDI) alpha Q5XI73 7 36 90 23393 
Rho-associated kinase 
beta AAB37571 24 18 71 159527 
 
Miscellaneous proteins 
Albumin precursor P02770 17 30 128 68674 
Poly-ubiquitin Q63654 5 44 82 11234 
Complement C3 
precursor 625256 13 7 61 186342 
Heme-binding 23K 
protein (HBP23) 1QQ2A 7 28 58 22095 
Putative alpha (1,3) 
fucosyltransferase CAC81972 10 19 59 42931 
Periaxin I58157 19 13 102 146948 
Carbonic anhydrase IV AAH97329 10 25 72 35054 
Heat shock 70kDa 
protein 5 AAH62017 19 33 95 72302 
Protein disulfide 
isomerase associated 3 AAH62393 16 32 95 56588 
Transferrin  AAP97736 14 19 80 76346 
Ferroxidase precursor A35210 11 9 122 120588 
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RSB-11-77 protein NP_872610 12 28 75 42058 
Cytochrome b5 AAB67609 13 27 78 11400 
 
Calreticulin is a Ca2+-binding protein for the calcium storage in ER [258]. It also 
has been reported to act as an important modulator of the regulation of gene transcription 
by nuclear hormone receptors [259]. Lamellar bodies contain a high level of calcium, 
especially lamellar bodies in apical area and the exocytotic lamellar bodies contain 
significantly higher calcium compared to those in perinuclear area [260]. This suggests 
that this high content of calcium in lamellar bodies may be a supply for the increase in 
local calcium concentration during the fusion events. Calreticulin may be the main 
calcium holder in lamellar bodies and may control the release of the calcium ions. 
Annexins are important Ca2+-binding proteins. Their functions include membrane 
organization, membrane-cytoskeleton linkage, membrane transportation and ion 
conductance across membranes. Annexin A1-7 were identified in lamellar bodies in this 
study. Annexin A1, 2, 3, 6 have been reported in type II cells with immunobolting and 
annexin A4 and A5 were not detected in this study [118]. Mayran et al. reported the 
presence of annexin A1, 4 and 6 in type II cells by using immunohistochemistry [261]. 
Annexin A5 was reported to be secreted from type II cells and its secretion was 
stimulated by TPA but inhibited by SP-A, showing the same pattern as that of surfactant 
secretion [262]. This suggests that annexin A5 may be released through lamellar bodies. 
Annexin A2 is important in various aspects of membrane trafficking [192, 193]. It 
mediates the fusion between lamellar bodies and the plasma membrane [112] and has 
been shown to be required in regulated lung surfactant secretion [214]. In addition to 
annexin A2, annexin A7 also has been proposed to be involved in regulating lung 
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surfactant secretion [119, 263, 264]. Annexin A1 and A6 have been reported to play roles 
in endocytosis [265, 266]. The presence of annexin A2 in lamellar bodies is in line with 
its role in surfactant secretion. The identification of other annexins may indicate their 
functions at other aspects, such as intracellular translocation.  
It has been reported that actin [114] and microtubules [115] play a role in the 
transportation of lamellar bodies. In stimulated type II cells, annexin A2 may be involved 
in the disassembly and assembly of the cytoskeleton [117]. The identification of several 
cytoskeletal protins and actin-binding proteins (Beta-actin, Vimentin, Myosin-9, Moesin 
etc.) in lamellar bodies may suggest these proteins are involved in the movement of 
lamellar bodies. 
An interesting protein identified is Ehd1, which stands for the EH domain-
containing 1 protein. The EH domain includes an EF-Ca2+-binding motif, a highly 
conserved ATP/GTP-binding domain, and a central coiled-coil structure [267]. It has 
been reported that Ehd1 interacts with SNAP-29 and plays a role in the endocytosis of 
Insulin-like Growth Factor 1 (IGF1) receptors [268]. Its role in the regulation of 
endocytic recycling has been further confirmed in other systems [269]. 
Rab proteins are small GTP-binding proteins that play roles in vesicular 
trafficking of molecules between cellular organelles. They serve as functional switches 
for the GTP-GDP exchange reaction.Rab GDP dissociation inhibitors (GDIs) can reduce 
the rate of GDP dissociation from Rab proteins [270]. Rab GDI alpha has been reported 
to bind Rab3A and modulates their activity and vesicle-mediated transport [271]. The 
identification of GDI alpha in lamellar bodies suggests that it may be involved in the 
docking of lamellar bodies at the plasma membrane.  
 89
Lamellar bodies are lysosome-related organelles and retain some lysosoma-like 
features. Along with lysosome membrane protein II, some proteases (Dipeptidyl 
peptidase IV) and protease inhibitors (Serpinh1 and alpha-1-antitrypsin precursor) were 
identified, which suggests that lamellar bodies may not only store surfactant, they may 
also play a role in surfactant processing or remodeling. We also identified the proton 
transporting ATPases (H+-transporting two-sector ATPase alpha chain precursor and F1-
ATPase beta chain). These ATPases can pump protons into lamellar bodies to maintain 
the low pH inside lamellar bodies[77, 272], which is essential for surfactant processing 
[75, 273, 274] and Ca2+ uptake [275].   
Some other proteins involved in lamellar body biogenesis were also identified. 
ABCA3 is a unique type II cell marker that is thought to transport lipids to lamellar 
bodies [79, 82]. Peroxiredoxin-6, which possesses both phospholipase A2 and peroxidase 
activity [276], is responsible for the degradation of recycled DPPC in type II cell [277]. 
Apolipoprotein A-I is the major apoprotein of high-density-lipoprotein (HDL). The 
identification of apolipoproteins in lamellar bodies suggests that the cholesterol of 
surfactant may originate from HDL.  
There are some limitations of the current techniques. For example, many 
membrane proteins are difficult to dissolve or precipitate during IEF. Proteins with 
extreme large or small sizes or pI values are also very difficult to identify. Additionally, a 
large amount of peptides are required to yield a satisfactory mass spectrum. Many 
proteins in lamellar bodies may be functionally important, but are not abundant enough to 
be detected. We had many spots yield good mass spectra, but no high data matches were 
found. This is possibly due to the limitation of Rattus database.   
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 In summary, the proteomic profiling of lamellar bodies generated from this study 
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V. SUMMARIES AND CONCLUSIONS 
 
Lung surfactant secretion is a slow but highly regulated process and the secreted 
contents are unique lipo-protein complexes. Thus, it is not surprising that surfactant 
secretion has its different aspects from the neurotransmitter release in synapses or 
hormone secretion in endocrine systems. So far, the underlying principles of surfactant 
secretion are still not clear. In this dissertation, an attempt to elucidate the molecular 
mechanisms of the regulated lung surfactant has been made from three aspects. 
Based on our previous studies, SNARE proteins are present in type II cells and 
required for regulated lung surfactant secretion. However, the SNARE proteins have not 
been shown to have the capability to sense the elevation of cytoplasmic Ca2+, nor mediate 
the membrane fusion directly. On the other hand, the Ca2+-binding protein, annexin A2, 
has been reported to mediate the fusion of lamellar bodies and the plasma membrane and 
promote surfactant secretion in type II cells. The aim of the first aspect of this project was 
to investigate whether annexin A2 works with SNARE proteins in the same pathway, 
acting as a Ca2+ sensor and fusogen (Chapter II). To test the interaction between annexin 
A2 and SNARE proteins, a GST fusion protein pull-down assay was utilized. SNAP-23 
showed a specific binding with annexin A2 in a Ca2+-dependent manner, while syntaxin 
and VAMP families had no significant binding. The interaction between SNAP-23 and 
annexin A2 was confirmed with a mammalian two-hybrid assay. These two proteins were 
co-localized in type II cells by immunocytochemistry. To identify the binding sites of 
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SNAP-23, a series of deletion mutants were constructed and applied to GST pull-down 
assay. The deletion of the cysteine-rich region (CRR) of SNAP-23 abolished its binding 
with annexin A2. The mutations of the cysteine residues rendered SNAP-23 to lose its 
binding with annexin A2. Furthermore, annexin A2 was able to co-immunoprecipitated 
with wild type SNAP-23 but not with CRR deleted SNAP-23 mutant. These results 
indicated that CRR is required for the interaction between SNAP-23 and annexin A2. To 
study their functional interaction, an in vitro membrane fusion model was utilized. Anti-
SNAP-23 antibodies inhibited the annexin A2-mediated fusion between isolated lamellar 
bodies and the plasma membrane. All these results supported that annexin A2 functions 
together with SNARE proteins in regulated surfactant secretion through its interaction 
with SNAP-23. 
We have previously demonstrated the involvement of t-SNAREs, syntaxin 2 and 
SNAP-23, in regulated surfactant secretion. The second aspect of my work was to 
characterize the v-SNARE proteins involved (Chapter III). The gene expression of 
VAMP isoforms was detected by using RT-PCR, and VAMP-2, -3 and -8 had strong 
expression in lung and type II cells. The protein expression patterns of VAMP-2, -3 and -
8 at various fractions of lung and type II cells were detected with Western blotting. 
VAMP-2 and VAMP-8 were present in type II cells and enriched in lamellar body 
fraction, whereas VAMP-3 was mainly present at plasma membrane fraction. 
Furthermore, immunostaining studies showed that VAMP-2 was localized on lamellar 
bodies, while VAMP-8 had more diffusible distribution with a partial localization on 
lamellar bodies. There studies suggest that VAMP-2 may be the v-SNARE protein 
involved in surfactant secretion. 
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Lamellar bodies are lysosome-related organelles and have unique features. Taking 
the advantage of the powerful sub-cellular proteomic techniques, a proteomic analysis of 
lamellar body proteins was carried out. Highly-purified lamellar bodies were applied to 
one- or two-dimensional polyacrylamide gel electrophoresis and MALDI-TOF mass 
spectrometry was performed. 44 proteins were identified and categorized according to 
their possible functions, including membrane trafficking, calcium binding and lamellar 
body related functions. This proteomic profiling of lamellar body proteins provides a 
base to better understand the biogenesis and function of lamellar bodies. 
In summary, we demonstrated that annexin A2 physically and functionally 
interacted with SNAP-23. We also characterized VAMP proteins in lung and type II cells. 
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Scope and Method of Study:  
 This project was to study the molecular mechanisms of lung surfactant secretion 
from three aspects. The first part was to investigate the interaction between SNARE 
proteins and annexin A2. GST-tagged protein pull-down assay was the major technique 
utilized. The physical interaction of recombinant GST-tagged SNARE proteins with 
annexin A2 were tested. To confirm the interaction between annexin A2 and SNAP-23, 
additional methods were used, including co-immunoprecipitation, mammalian two-
hybrid assays. Immunocytochemistry was used to study the co-localization of annexin A2 
and SNAP-23. Deletion and site-directed mutagenesis were used to identify the binding 
sites for annexin A2 on SNAP-23. Furthermore, an in vitro bio-membrane fusion assay 
was utilized to study the functional interaction between annexin A2 and SNAP-23. The 
second part was to identify the v-SNARE protein involved in regulated surfactant 
secretion. Various VAMP genes were amplified from alveolar type II cells by using RT-
PCR. The expression of VAMP proteins were detected with Western blotting. 
Immunohistochemistry and immunocytochemistry were utilized to study the localization 
of VAMP in lung and type II cells. In the third part, the proteomic profile of lamellar 
bodies was analyzed. Lamellar bodies were isolated from rat lungs and the proteins were 
separated with 1-D and 2-D SDS-PAGE. The proteins were applied to MALDI-TOF MS, 
and identified by searching the peptide spectra against the Mass Spectrometry protein 
sequence Database (MSDB) using the Mascot web based search engine. 
 
Findings and Conclusions:   
I. 
1. SNAP-23 specifically binds with annexin A2 in a Ca2+-dependent manner.  
2. The cysteine rich domain of SNAP-23 is required for its binding with annexin A2.  
3. SNAP-23 is required in annexin A2 tetramer mediated membrane fusion between 
isolated lamellar bodies and the plasma membrane.  
II. 
1. VAMP-2 and -8 are expressed in type II cells and lamellar bodies. 
2. VAMP-2 is localized on lamellar bodies and VAMP-8 is partially localized on 
lamellar bodies. 
III. 
1. Forty-four proteins in lamellar bodies were identified. 
2. Proteins involved in membrane trafficking and Ca2+-binding may play roles in 
lamellar body biogenesis and fusion with the plasma membrane. 
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